Hennekam lymphangiectasia-lymphedema syndrome 2

Mendelian MONDO:0014454 Pathograph 14 Show in embeddings browser Hennekam syndrome hereditary disease

Hennekam lymphangiectasia-lymphedema syndrome 2 (HKLLS2) is an autosomal recessive generalized lymphatic dysplasia caused by biallelic mutations in FAT4. Like the CCBE1-related form, it presents with intestinal lymphangiectasia, peripheral and facial lymphedema, a characteristic flat facial gestalt, and mild to moderate intellectual disability. FAT4 was identified as a Hennekam gene through the original 1989 Hennekam family, in whom no CCBE1 mutation was found; it accounts for a subset of CCBE1 mutation-negative cases. FAT4 is a giant atypical (protocadherin) cadherin that partners with Dachsous1 (DCHS1) in planar cell polarity signaling (with context-dependent Hippo-pathway crosstalk) to control lymphatic endothelial cell polarization and lymphatic valve morphogenesis. Biallelic FAT4 loss is allelic to Van Maldergem syndrome, with which HKLLS2 shares a facial gestalt and intellectual disability but which is distinguished by neonatal hypotonia, hearing loss, tracheal anomalies, and osteopenia rather than prominent lymphedema.

Ask OpenScientist

Ask a research question about Hennekam lymphangiectasia-lymphedema syndrome 2. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
7
Pathophys.
17
Phenotypes
14
Pathograph
1
Genes
4
Medical Actions
3
Differentials
2
Deep Research
🏷

Classifications

Harrison's Part
GENETICS ENVIRONMENT DISEASE
IUIS Category
combined immunodeficiency with syndromic features
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
HKLLS2 is inherited in an autosomal recessive manner; affected individuals carry biallelic (homozygous or compound heterozygous) FAT4 mutations, frequently with parental consanguinity.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:24913602 SUPPORT Human Clinical
"Subsequent targeted mutation analysis of FAT4 in a cohort of 24 CCBE1 mutation-negative Hennekam syndrome patients identified homozygous or compound heterozygous mutations in four additional families."
Homozygous and compound heterozygous FAT4 genotypes establish autosomal recessive inheritance for HKLLS2.
⚙

Pathophysiology

7
FAT4 loss of function
Biallelic loss-of-function mutations in FAT4, a giant atypical protocadherin, disrupt Dachsous1-FAT4 planar cell polarity signaling (with context-dependent Hippo-pathway involvement) required for normal lymphatic development.
FAT4 hgnc:23109 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves FAT4 (hgnc:23109). hgnc:23109 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Dysregulated Hippo-YAP signaling in cortical neural progenitors The same biallelic FAT4 loss removes FAT4-DCHS1 restraint on YAP in the embryonic neuroepithelium, which is the neurodevelopmental arm of the phenotype and runs parallel to the lymphatic arm.
Impaired lymphatic valve morphogenesis FAT4, with its ligand Dachsous1, controls planar cell polarity of valve endothelial cells; loss disrupts lymphatic valve leaflet formation.
Show evidence (2 references)
PMID:24913602 SUPPORT Human Clinical
"We used homozygosity mapping and whole-exome sequencing in the original HS family with multiple affected individuals in whom no CCBE1 mutation had been detected, and identified a homozygous mutation in the FAT4 gene."
Identifies FAT4 as a causal Hennekam syndrome gene, discovered in the original Hennekam family.
PMID:36797229 SUPPORT In Vitro
"The binding domains of Fat4 and Dchs1 form an extended interface along extracellular cadherin (EC) domains 1-4 of each protein."
The FAT4-DCHS1 co-crystal structure defines the molecular basis of the receptor-ligand pair whose disruption underlies HKLLS2.
Impaired lymphatic valve morphogenesis
Disrupted FAT4-dependent planar cell polarity leaves lymphatic valve endothelial cells disoriented and unable to form proper valve leaflets, impairing lymphatic drainage.
lymphatic endothelial cell CL:0002138 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves lymphatic endothelial cell, annotated with endothelial cell of lymphatic vessel (CL:0002138). CL:0002138 is a cell type from the Cell Ontology.
DCHS1 hgnc:13681 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves DCHS1 (hgnc:13681). hgnc:13681 is a gene from the HUGO Gene Nomenclature Committee.
establishment of planar polarity GO:0001736 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves establishment of planar polarity (GO:0001736). GO:0001736 is a biological process from the Gene Ontology.
Downstream
Generalized lymphatic dysplasia Defective lymphatic valve morphogenesis and drainage produce dysfunctional lymphatics.
Show evidence (2 references)
PMID:28705793 SUPPORT Model Organism
"This study highlights that valve defects may contribute to lymphedema in Hennekam syndrome caused by Fat4 mutations."
The authors conclude from their mouse data that valve defects may contribute to the lymphedema of FAT4-related Hennekam syndrome; the link is proposed rather than demonstrated in patients.
PMID:32182215 SUPPORT Model Organism
"control cell polarity in response to flow and is required for lymphatic vessel morphogenesis throughout development."
Demonstrates that FAT4 controls lymphatic endothelial cell polarity in response to flow and is required for lymphatic vessel morphogenesis, the flow-responsive arm of the mechanism.
Generalized lymphatic dysplasia
Lymphatic dysfunction impairs lymph drainage and underlies the intestinal lymphangiectasia and lymphedema of the syndrome.
lymphatic endothelial cell CL:0002138 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves lymphatic endothelial cell, annotated with endothelial cell of lymphatic vessel (CL:0002138). CL:0002138 is a cell type from the Cell Ontology.
Downstream
Intestinal lymphangiectasia Dysplastic intestinal lymphatics dilate and leak lymph into the gut lumen.
Lymphedema Impaired lymphatic drainage in the limbs, genitalia, and face causes lymphedema.
Show evidence (1 reference)
PMID:2624276 SUPPORT Human Clinical
"We report on two male and two female relatives with intestinal lymphangiectasia; severe lymphedema of limbs, genitalia, and face; facial anomalies; seizures; mild growth retardation; and moderate mental retardation."
The original Hennekam family, later shown to carry biallelic FAT4 mutations (PMID:24913602), showed generalized lymphatic involvement (intestinal lymphangiectasia plus lymphedema of limbs, genitalia, and face).
Intestinal lymphangiectasia
Dilated intestinal lymphatics leak protein-rich lymph into the gut, producing protein-losing enteropathy with hypoalbuminemia, hypogammaglobulinemia, and lymphopenia.
Downstream
Protein-losing enteropathy Enteric loss of lymph depletes serum albumin and immunoglobulins.
Show evidence (1 reference)
PMID:2624276 SUPPORT Human Clinical
"We report on two male and two female relatives with intestinal lymphangiectasia; severe lymphedema of limbs, genitalia, and face; facial anomalies; seizures; mild growth retardation; and moderate mental retardation."
The original Hennekam family, later shown to carry biallelic FAT4 mutations (PMID:24913602), had intestinal lymphangiectasia as a core feature.
Protein-losing enteropathy
Protein-rich lymph lost into the gut lumen produces protein-losing enteropathy, depleting serum albumin, immunoglobulins, and lymphocytes.
Downstream
Hypoalbuminemia Enteric protein loss lowers serum albumin.
Decreased circulating immunoglobulin concentration Enteric loss of lymph depletes serum immunoglobulins.
Lymphopenia Enteric loss of lymph depletes circulating lymphocytes.
Show evidence (1 reference)
PMID:29560340 SUPPORT Human Clinical
"both gastrointestinal protein loss and malabsorption"
Intestinal lymphangiectasia in Hennekam syndrome causes gastrointestinal protein loss (protein-losing enteropathy) and malabsorption.
Dysregulated Hippo-YAP signaling in cortical neural progenitors
The second arm of FAT4 loss, independent of the lymphatic arm above. FAT4 and its ligand DCHS1 act upstream of the Hippo effector YAP in the embryonic neuroepithelium. Losing that restraint expands the neural progenitor pool at the expense of neuronal differentiation. The YAP dependence is established by epistasis - concurrent Yap knockdown rescues the phenotype - rather than by direct measurement of Hippo pathway flux, which is why the pathway modifier here should be read as loss of FAT4-mediated restraint on YAP.
cortical neural progenitor cell CL:0011020 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cortical neural progenitor cell, annotated with neural progenitor cell (CL:0011020). CL:0011020 is a cell type from the Cell Ontology.
hippo signaling GO:0035329 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased hippo signaling (GO:0035329). GO:0035329 is a biological process from the Gene Ontology. neural precursor cell proliferation GO:0061351 ↑ INCREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased neural precursor cell proliferation (GO:0061351). GO:0061351 is a biological process from the Gene Ontology. neuron differentiation GO:0030182 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased neuron differentiation (GO:0030182). GO:0030182 is a biological process from the Gene Ontology.
Downstream
Periventricular neuronal heterotopia Progenitors that over-proliferate and fail to differentiate accumulate below the neuronal layers instead of migrating into the cortical plate.
Show evidence (2 references)
PMID:24056717 SUPPORT Model Organism
"Reducing the expression of Dchs1 or Fat4 within mouse embryonic neuroepithelium increased progenitor cell numbers and reduced their differentiation into neurons"
Establishes the cellular consequence of Fat4 loss in the developing cortex: progenitor expansion with reduced neuronal differentiation.
PMID:24056717 SUPPORT Model Organism
"These effects were countered by concurrent knockdown of Yap, a transcriptional effector of the Hippo signaling pathway."
The epistasis result placing FAT4 upstream of YAP, which is the basis for naming this node after the Hippo-YAP axis rather than after FAT4 alone.
Periventricular neuronal heterotopia
Nodules of neurons arrested near the ventricular surface rather than migrating to the cortical plate. This is the structural lesion that carries the neurodevelopmental features of the FAT4 phenotypes, and it is what makes the intellectual disability and seizures of this entry mechanistically connected rather than incidental.
Downstream
Intellectual disability Disrupted cortical lamination underlies the mild to moderate intellectual disability shared by the FAT4-related phenotypes.
Seizure Heterotopic grey matter is an epileptogenic substrate, which is the mechanistic route to the seizures recorded in this entry.
Show evidence (1 reference)
PMID:24056717 SUPPORT PRIMARY RESULT Human Clinical
"mutations in genes encoding the receptor-ligand cadherin pair DCHS1 and FAT4 lead to a recessive syndrome in humans that includes periventricular neuronal heterotopia"
Establishes periventricular neuronal heterotopia in the human biallelic FAT4 phenotype. The patients reported here are the Van Maldergem end of the FAT4 spectrum, so this is cited for the shared consequence of FAT4 loss rather than as an HKLLS2 cohort finding.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Hennekam lymphangiectasia-lymphedema syndrome 2 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

17
Blood 2
Decreased circulating immunoglobulin concentration HP:0004313 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypogammaglobulinemia, annotated with Decreased circulating immunoglobulin concentration (HP:0004313). HP:0004313 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:29560340 SUPPORT Human Clinical
"severe protein loss resulting in hypogammaglobulinemia"
Enteric protein loss in Hennekam syndrome produces hypogammaglobulinemia.
PMID:18294365 SUPPORT INDIRECT Human Clinical
"responsible for protein-losing enteropathy leading to lymphopenia, hypoalbuminemia and hypogammaglobulinemia"
Corroborates hypogammaglobulinemia as a consequence of lymph loss in intestinal lymphangiectasia generally. Cited for the shared mechanism, not as HKLLS2-specific data.
Lymphopenia Decreased total lymphocyte count HP:0001888 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Lymphopenia, annotated with Decreased total lymphocyte count (HP:0001888). HP:0001888 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:18294365 SUPPORT INDIRECT Human Clinical
"Primary intestinal lymphangiectasia (PIL) is a rare disorder characterized by dilated intestinal lacteals resulting in lymph leakage into the small bowel lumen and responsible for protein-losing enteropathy leading to lymphopenia, hypoalbuminemia and hypogammaglobulinemia"
Establishes lymphopenia as a consequence of lymph loss in intestinal lymphangiectasia. Cited for the shared downstream mechanism rather than as HKLLS2-specific cohort data.
PMID:18294365 SUPPORT INDIRECT Human Clinical
"their risk of pyogenic bacterial infection is not significantly elevated"
The basis for the caution in the description. Recorded because an entry listing lymphopenia and hypogammaglobulinemia without it would imply an infection risk the literature does not support.
Cardiovascular 1
Intestinal lymphangiectasia HP:0002593 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intestinal lymphangiectasia (HP:0002593). HP:0002593 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:2624276 SUPPORT Human Clinical
"We report on two male and two female relatives with intestinal lymphangiectasia; severe lymphedema of limbs, genitalia, and face; facial anomalies; seizures; mild growth retardation; and moderate mental retardation."
Documents intestinal lymphangiectasia in the original Hennekam family, later shown to carry biallelic FAT4 mutations (PMID:24913602).
Digestive 1
Protein-losing enteropathy HP:0002243 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Protein-losing enteropathy (HP:0002243). HP:0002243 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29560340 SUPPORT Human Clinical
"Intestinal lymphangiectasia can lead to severe protein loss"
Documents that the intestinal lymphangiectasia of Hennekam syndrome causes severe enteric protein loss (protein-losing enteropathy).
Ear 1
Abnormality of the ear HP:0000598 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ear defects, annotated with Abnormality of the ear (HP:0000598). HP:0000598 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:2624276 SUPPORT Human Clinical
"Main facial anomalies are a flat face, flat nasal bridge, hypertelorism, small mouth, tooth anomalies, and ear defects."
Documents ear defects in the original Hennekam family, later shown to carry biallelic FAT4 mutations (PMID:24913602).
Eye 1
Hypertelorism HP:0000316 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypertelorism (HP:0000316). HP:0000316 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:2624276 SUPPORT Human Clinical
"Main facial anomalies are a flat face, flat nasal bridge, hypertelorism, small mouth, tooth anomalies, and ear defects."
Documents hypertelorism in the original Hennekam family, later shown to carry biallelic FAT4 mutations (PMID:24913602).
Head and Neck 4
Flat face HP:0012368 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Flat face (HP:0012368). HP:0012368 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:2624276 SUPPORT Human Clinical
"Main facial anomalies are a flat face, flat nasal bridge, hypertelorism, small mouth, tooth anomalies, and ear defects."
Documents a flat face in the original Hennekam family, later shown to carry biallelic FAT4 mutations (PMID:24913602).
Depressed nasal bridge HP:0005280 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Flat nasal bridge, annotated with Depressed nasal bridge (HP:0005280). HP:0005280 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:2624276 SUPPORT Human Clinical
"Main facial anomalies are a flat face, flat nasal bridge, hypertelorism, small mouth, tooth anomalies, and ear defects."
Documents a flat nasal bridge in the original Hennekam family, later shown to carry biallelic FAT4 mutations (PMID:24913602).
Narrow mouth HP:0000160 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Small mouth, annotated with Narrow mouth (HP:0000160). HP:0000160 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:2624276 SUPPORT Human Clinical
"Main facial anomalies are a flat face, flat nasal bridge, hypertelorism, small mouth, tooth anomalies, and ear defects."
Documents a small mouth in the original Hennekam family, later shown to carry biallelic FAT4 mutations (PMID:24913602).
Abnormal dental morphology HP:0006482 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Tooth anomalies, annotated with Abnormal dental morphology (HP:0006482). HP:0006482 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:2624276 SUPPORT Human Clinical
"Main facial anomalies are a flat face, flat nasal bridge, hypertelorism, small mouth, tooth anomalies, and ear defects."
Documents tooth anomalies in the original Hennekam family, later shown to carry biallelic FAT4 mutations (PMID:24913602).
Metabolism 2
Lymphedema HP:0001004 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Lymphedema (HP:0001004), qualified as temporality chronic. HP:0001004 is a phenotype from the Human Phenotype Ontology.
Temporal: CHRONIC
Show evidence (2 references)
PMID:29681106 SUPPORT Human Clinical
"Both conditions are characterized by a typical facial gestalt and mild to moderate intellectual disability, but differ in the occurrence of neonatal hypotonia and feeding problems, hearing loss, tracheal anomalies, and osteopenia in VMS, and lymphedema in HS."
Lymphedema is the key feature distinguishing FAT4-related Hennekam syndrome from allelic Van Maldergem syndrome.
DOI:10.1172/JCI99027 SUPPORT Other
"the onset of lymphedema in patients with CCBE1 has been reported from birth, whereas lymph edema can occur at a later point in Hennekam syndrome caused by FAT4 mutations"
Source for the later onset of lymphedema in FAT4-related Hennekam syndrome compared with the CCBE1-related form, as stated in this phenotype's description; the authors present it as what has been reported in the patients studied to date.
Hypoalbuminemia HP:0003073 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypoalbuminemia (HP:0003073). HP:0003073 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:18294365 SUPPORT INDIRECT Human Clinical
"Primary intestinal lymphangiectasia (PIL) is a rare disorder characterized by dilated intestinal lacteals resulting in lymph leakage into the small bowel lumen and responsible for protein-losing enteropathy leading to lymphopenia, hypoalbuminemia and hypogammaglobulinemia"
Establishes hypoalbuminemia as a consequence of the protein-losing enteropathy caused by intestinal lymphangiectasia. This source describes primary (Waldmann) intestinal lymphangiectasia rather than FAT4-related Hennekam syndrome, and is cited for the shared downstream consequence of dilated intestinal lacteals, not as HKLLS2-specific data.
Musculoskeletal 2
Camptodactyly HP:0012385 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Camptodactyly (HP:0012385). HP:0012385 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41992670 SUPPORT Human Clinical
"We herein report a 15-month-old male with peripheral lymphedema, facial dysmorphism, camptodactyly and generalized hypotonia"
Reports camptodactyly in a patient with a confirmed biallelic FAT4 splice variant, so the finding is observed in genetically established HKLLS2 rather than in the clinically defined syndrome at large.
Generalized hypotonia HP:0001290 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Generalized hypotonia (HP:0001290). HP:0001290 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41992670 SUPPORT Human Clinical
"We herein report a 15-month-old male with peripheral lymphedema, facial dysmorphism, camptodactyly and generalized hypotonia"
Reports generalized hypotonia in a patient with a confirmed biallelic FAT4 splice variant, establishing the feature in genetically confirmed HKLLS2.
Nervous System 2
Intellectual disability HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29681106 SUPPORT Human Clinical
"Both conditions are characterized by a typical facial gestalt and mild to moderate intellectual disability"
Mild to moderate intellectual disability is documented in FAT4-related Hennekam syndrome.
Seizure FREQUENT HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizures, annotated with Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:29560340 SUPPORT Human Clinical
"About 33% of cases of Hennekam syndrome patients have seizures, varying from absences to tonic or atonic attacks"
Quantifies seizures at about 33% of Hennekam syndrome patients (FREQUENT band, 30-79%) and gives the semiology. The figure is for Hennekam syndrome across molecular subtypes, not for FAT4-related disease specifically.
PMID:2624276 SUPPORT Human Clinical
"We report on two male and two female relatives with intestinal lymphangiectasia; severe lymphedema of limbs, genitalia, and face; facial anomalies; seizures; mild growth retardation; and moderate mental retardation."
Documents seizures in the original Hennekam family, later shown to carry biallelic FAT4 mutations (PMID:24913602).
Growth 1
Growth delay HP:0001510 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Growth retardation, annotated with Growth delay (HP:0001510). HP:0001510 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:2624276 SUPPORT Human Clinical
"We report on two male and two female relatives with intestinal lymphangiectasia; severe lymphedema of limbs, genitalia, and face; facial anomalies; seizures; mild growth retardation; and moderate mental retardation."
Mild growth retardation was documented in the original Hennekam family, which was later shown to carry biallelic FAT4 mutations (PMID:24913602).
🧬

Genetic Associations

1
FAT4 (Causal biallelic loss-of-function variant)
Gene: FAT4 hgnc:23109 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is FAT4 (hgnc:23109). hgnc:23109 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (4 references)
PMID:24913602 SUPPORT Human Clinical
"We conclude that Hennekam syndrome can be caused by mutations in FAT4 and be allelic to Van Maldergem syndrome."
Establishes FAT4 as a causal gene for Hennekam syndrome, allelic to Van Maldergem syndrome.
PMID:29681106 SUPPORT Human Clinical
"Biallelic variants in FAT4 are associated with the two disorders, Van Maldergem syndrome (VMS) (n = 11) and Hennekam syndrome (HS) (n= 40)."
Confirms biallelic FAT4 variants as a cause of Hennekam syndrome in an independent cohort.
PMID:24913602 SUPPORT Human Clinical
"Subsequent targeted mutation analysis of FAT4 in a cohort of 24 CCBE1 mutation-negative Hennekam syndrome patients identified homozygous or compound heterozygous mutations in four additional families."
Documents the FAT4 variant classes causing HKLLS2 (homozygous or compound heterozygous), consistent with biallelic recessive loss of function.
+ 1 more reference
💊

Medical Actions

4
Dietary management of protein-losing enteropathy
Action: dietary interventionNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is dietary intervention (NCIT:C15447). NCIT:C15447 is a clinical intervention from the NCI Thesaurus. Ontology label: Dietary Intervention NCIT:C15447
Platform: Behavioral / lifestyle
A low-fat diet with medium-chain triglyceride supplementation is the mainstay of management for the protein-losing enteropathy. The mechanism is specific rather than merely nutritional: withholding long-chain fat prevents chyle engorging the intestinal lymphatics and so prevents the rupture through which lymph is lost, while medium-chain triglycerides are absorbed directly into the portal circulation and bypass the lacteals altogether. Dietary control generally needs to be permanent, because clinical and biochemical abnormalities return when the low-fat diet is withdrawn.
Show evidence (4 references)
PMID:29560340 SUPPORT Human Clinical
"patients may require a high-protein, low-fat diet with medium-chain triglyceride supplementation in the case"
Directly supports a high-protein, low-fat, medium-chain-triglyceride diet for the protein-losing enteropathy of Hennekam syndrome.
PMID:18294365 SUPPORT INDIRECT Human Clinical
"A low-fat diet associated with medium-chain triglyceride supplementation is the cornerstone of PIL medical management."
Establishes the dietary regimen as first-line management of intestinal lymphangiectasia. This replaces an earlier evidence item on this record that quoted only the title of the 1989 clinical report, which described the syndrome but said nothing about diet. Cited for the shared management of intestinal lymphangiectasia rather than as HKLLS2-specific trial data.
PMID:18294365 SUPPORT INDIRECT Human Clinical
"The absence of fat in the diet prevents chyle engorgement of the intestinal lymphatic vessels thereby preventing their rupture with its ensuing lymph loss. Medium-chain triglycerides are absorbed directly into the portal venous circulation and avoid lacteal overloading."
Gives the mechanism recorded in the description, which is what makes this a mechanism-directed rather than a merely supportive intervention.
+ 1 more reference
Lymphedema supportive care
Action: physical therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is physical therapy (NCIT:C15302). NCIT:C15302 is a clinical intervention from the NCI Thesaurus. Ontology label: Physical Therapy NCIT:C15302
Platform: Behavioral / lifestyle
Complete decongestive therapy (compression, manual lymphatic drainage, exercise, skin care) manages the lymphedema and reduces cellulitis risk.
Show evidence (2 references)
PMID:29560340 SUPPORT Human Clinical
"rehabilitative treatments including complete decongestive therapy for edema control appeared to be beneficial"
The case report concludes that complete decongestive therapy was beneficial for edema control in a patient with Hennekam syndrome.
PMID:29681106 SUPPORT Human Clinical
"but differ in the occurrence of neonatal hypotonia and feeding problems, hearing loss, tracheal anomalies, and osteopenia in VMS, and lymphedema in HS."
Establishes lymphedema as the feature that distinguishes FAT4-related Hennekam syndrome from allelic Van Maldergem syndrome, i.e. that this therapy has a target in HKLLS2; it says nothing about the therapy itself.
Supportive and multidisciplinary care
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Management is symptomatic and multidisciplinary, including nutritional support, monitoring for hypoalbuminemia and immunodeficiency, developmental and educational support, and treatment of seizures.
Show evidence (1 reference)
PMID:2624276 SUPPORT Human Clinical
"We report on two male and two female relatives with intestinal lymphangiectasia; severe lymphedema of limbs, genitalia, and face; facial anomalies; seizures; mild growth retardation; and moderate mental retardation."
The multisystem features require symptomatic multidisciplinary care.
Genetic counseling
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Counsel families about autosomal recessive inheritance, 25% sibling recurrence risk, carrier testing, the allelic relationship to Van Maldergem syndrome, and reproductive options.
Show evidence (1 reference)
PMID:24913602 SUPPORT Human Clinical
"We conclude that Hennekam syndrome can be caused by mutations in FAT4 and be allelic to Van Maldergem syndrome."
The allelic relationship to Van Maldergem syndrome and recessive inheritance inform genetic counseling.
🔬

Diagnosis

1
Molecular genetic testing of FAT4
Sequencing and deletion/duplication analysis of FAT4, typically within a primary-lymphedema/generalized-lymphatic-dysplasia gene panel or by exome sequencing, confirms the diagnosis in CCBE1 mutation-negative patients.
genetic testing NCIT:C15709 NCI Thesaurus (NCIT)
Results: Biallelic pathogenic FAT4 variants confirm HKLLS2.
Show evidence (1 reference)
PMID:24913602 SUPPORT Human Clinical
"Subsequent targeted mutation analysis of FAT4 in a cohort of 24 CCBE1 mutation-negative Hennekam syndrome patients identified homozygous or compound heterozygous mutations in four additional families."
Supports FAT4 molecular testing in CCBE1 mutation-negative Hennekam syndrome.
📊

Prevalence

1
Worldwide
Cases In Literature Ultra Rare
Hennekam syndrome is ultra-rare. A 2018 review of FAT4-associated phenotypes tabulated 40 reported patients with Hennekam syndrome and 11 with Van Maldergem syndrome; the paper does not say what share of those 40 carried FAT4 rather than CCBE1 or ADAMTS3 variants, so the count is reported here only as an indication of how few patients have been described. FAT4 accounts for a subset of CCBE1 mutation-negative cases.
Show evidence (1 reference)
PMID:29681106 SUPPORT Human Clinical
"Biallelic variants in FAT4 are associated with the two disorders, Van Maldergem syndrome (VMS) (n = 11) and Hennekam syndrome (HS) (n= 40)."
Documents the small number of reported Hennekam syndrome patients, underscoring the disorder's rarity.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Hennekam lymphangiectasia-lymphedema syndrome 2:

Van Maldergem syndrome 2 Not Yet Curated MONDO:0014242
Overlapping Features Van Maldergem syndrome 2 is the FAT4-related form, and so is allelic to HKLLS2 (both caused by biallelic FAT4 variants). It shares a facial gestalt and intellectual disability, but is distinguished by neonatal hypotonia, hearing loss, tracheal anomalies, and osteopenia rather than prominent lymphedema. Van Maldergem syndrome 1 (MONDO:0011070) is the DCHS1-related form and is not allelic to this entry.
Show evidence (1 reference)
PMID:29681106 SUPPORT Human Clinical
"Both conditions are characterized by a typical facial gestalt and mild to moderate intellectual disability, but differ in the occurrence of neonatal hypotonia and feeding problems, hearing loss, tracheal anomalies, and osteopenia in VMS, and lymphedema in HS"
Sets out the features shared by the two allelic FAT4 disorders and the ones that separate them, which is the basis for this differential.
Hennekam lymphangiectasia-lymphedema syndrome 1 MONDO:0009337
Overlapping Features CCBE1-related Hennekam syndrome is clinically overlapping and accounts for ~25% of cases; it is distinguished from the FAT4-related form by molecular testing.
Show evidence (1 reference)
PMID:24913602 SUPPORT Human Clinical
"It can be caused by mutations in CCBE1 which are found in approximately 25 % of cases"
Establishes CCBE1-related Hennekam syndrome as the alternative molecular cause that must be distinguished from the FAT4-related form, and gives the share of cases it accounts for.
Hennekam lymphangiectasia-lymphedema syndrome 3 Not Yet Curated MONDO:0032564
Overlapping Features ADAMTS3-related Hennekam syndrome is the third molecular form. ADAMTS3 acts with CCBE1 to cleave and activate VEGF-C, a pathway distinct from the FAT4-DCHS1 planar cell polarity axis of HKLLS2, so the forms are separated by molecular testing rather than by clinical features.
Show evidence (2 references)
PMID:29681106 SUPPORT Human Clinical
"VMS can be caused by autosomal recessive variants in DCHS1 as well, and HS can also be caused by autosomal recessive variants in CCBE1 and ADAMTS3"
Names ADAMTS3 as a further autosomal recessive cause of Hennekam syndrome, establishing the ADAMTS3-related form as a molecular differential for the FAT4-related form curated here.
PMID:32182215 SUPPORT Model Organism
"Hennekam syndrome is also caused by mutations in collagen and calcium binding EGF domains 1 (CCBE1) and ADAM metallopeptidase with thrombospondin type 1 motif 3 (ADAMTS3), encoding a matrix protein and protease, respectively, that regulate activity of the key prolymphangiogenic VEGF-C/VEGFR3..."
States outright that ADAMTS3 mutations cause Hennekam syndrome, and substantiates the mechanistic contrast drawn in this differential's description: ADAMTS3 acts with CCBE1 on the VEGF-C/VEGFR3 axis, a pathway distinct from the FAT4-DCHS1 planar cell polarity axis of HKLLS2.
{ }

Source YAML

click to show 
name: Hennekam lymphangiectasia-lymphedema syndrome 2
creation_date: "2026-08-02T00:00:00Z"
description: >-
  Hennekam lymphangiectasia-lymphedema syndrome 2 (HKLLS2) is an autosomal
  recessive generalized lymphatic dysplasia caused by biallelic mutations in
  FAT4. Like the CCBE1-related form, it presents with intestinal
  lymphangiectasia, peripheral and facial lymphedema, a characteristic flat
  facial gestalt, and mild to moderate intellectual disability. FAT4 was
  identified as a Hennekam gene through the original 1989 Hennekam family, in
  whom no CCBE1 mutation was found; it accounts for a subset of CCBE1
  mutation-negative cases. FAT4 is a giant atypical (protocadherin) cadherin
  that partners with Dachsous1 (DCHS1) in planar cell polarity signaling (with
  context-dependent Hippo-pathway crosstalk) to control lymphatic endothelial
  cell polarization and lymphatic valve morphogenesis. Biallelic FAT4 loss is allelic to Van Maldergem syndrome,
  with which HKLLS2 shares a facial gestalt and intellectual disability but which
  is distinguished by neonatal hypotonia, hearing loss, tracheal anomalies, and
  osteopenia rather than prominent lymphedema.
category: Mendelian
parents:
- Hennekam syndrome
- hereditary disease
synonyms:
- FAT4 Hennekam syndrome
- HKLLS2
- Hennekam syndrome type 2
disease_term:
  preferred_term: Hennekam lymphangiectasia-lymphedema syndrome 2
  term:
    id: MONDO:0014454
    label: Hennekam lymphangiectasia-lymphedema syndrome 2
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
  iuis_category:
    classification_value: combined immunodeficiency with syndromic features
    notes: >-
      IUIS 2022 Table 2 (combined immunodeficiencies with associated or
      syndromic features), sub-section 9, Other Defects; the FAT4 (autosomal
      recessive) row within the "Hennekam-lymphangiectasia-lymphedema syndrome"
      row group, immediately following the CCBE1 row. The row records
      low/variable T and B cells with decreased immunoglobulins alongside the
      lymphangiectasia, lymphedema, and dysmorphic features.
    evidence:
    - reference: PMID:35748970
      reference_title: "Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        FAT4 AR 612411 Low/variable Low/variable
      explanation: >-
        The IUIS Table 2 Other Defects row assigning the FAT4 (autosomal
        recessive) form of Hennekam lymphangiectasia-lymphedema syndrome to the
        combined immunodeficiencies with syndromic features; the disease-name
        cell is carried by the preceding CCBE1 row of the same row group.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    HKLLS2 is inherited in an autosomal recessive manner; affected individuals
    carry biallelic (homozygous or compound heterozygous) FAT4 mutations,
    frequently with parental consanguinity.
  evidence:
  - reference: PMID:24913602
    reference_title: Hennekam syndrome can be caused by FAT4 mutations and be allelic to Van Maldergem syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Subsequent targeted mutation analysis of FAT4 in a cohort of 24 CCBE1
      mutation-negative Hennekam syndrome patients identified homozygous or
      compound heterozygous mutations in four additional families.
    explanation: >-
      Homozygous and compound heterozygous FAT4 genotypes establish autosomal
      recessive inheritance for HKLLS2.
pathophysiology:
- name: FAT4 loss of function
  biological_scale: MOLECULAR
  description: >-
    Biallelic loss-of-function mutations in FAT4, a giant atypical
    protocadherin, disrupt Dachsous1-FAT4 planar cell polarity signaling (with
    context-dependent Hippo-pathway involvement) required for normal lymphatic
    development.
  genes:
  - preferred_term: FAT4
    term:
      id: hgnc:23109
      label: FAT4
  evidence:
  - reference: PMID:24913602
    reference_title: Hennekam syndrome can be caused by FAT4 mutations and be allelic to Van Maldergem syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We used homozygosity mapping and whole-exome sequencing in the original HS
      family with multiple affected individuals in whom no CCBE1 mutation had
      been detected, and identified a homozygous mutation in the FAT4 gene.
    explanation: >-
      Identifies FAT4 as a causal Hennekam syndrome gene, discovered in the
      original Hennekam family.
  - reference: PMID:36797229
    reference_title: Structure of the planar cell polarity cadherins Fat4 and Dachsous1.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The binding domains of Fat4 and Dchs1 form an extended interface along
      extracellular cadherin (EC) domains 1-4 of each protein.
    explanation: >-
      The FAT4-DCHS1 co-crystal structure defines the molecular basis of the
      receptor-ligand pair whose disruption underlies HKLLS2.
  downstream:
  - target: Dysregulated Hippo-YAP signaling in cortical neural progenitors
    description: >-
      The same biallelic FAT4 loss removes FAT4-DCHS1 restraint on YAP in the
      embryonic neuroepithelium, which is the neurodevelopmental arm of the
      phenotype and runs parallel to the lymphatic arm.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24056717
      reference_title: Mutations in genes encoding the cadherin receptor-ligand pair DCHS1 and FAT4 disrupt cerebral cortical development.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        These findings implicate Dchs1 and Fat4 upstream of Yap as key
        regulators of mammalian neurogenesis.
      explanation: >-
        Places FAT4 upstream of YAP in neurogenesis, which is the link from the
        root FAT4 lesion to this node.
  - target: Impaired lymphatic valve morphogenesis
    description: >-
      FAT4, with its ligand Dachsous1, controls planar cell polarity of valve
      endothelial cells; loss disrupts lymphatic valve leaflet formation.
    evidence:
    - reference: PMID:28705793
      reference_title: Dachsous1-Fat4 Signaling Controls Endothelial Cell Polarization During Lymphatic Valve Morphogenesis-Brief Report.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        both genes are specifically required for lymphatic valve morphogenesis
      explanation: >-
        Mouse data show Fat4 (with Dachsous1) is required for valve endothelial
        cell polarization and valve leaflet formation.
- name: Impaired lymphatic valve morphogenesis
  biological_scale: CELLULAR
  description: >-
    Disrupted FAT4-dependent planar cell polarity leaves lymphatic valve
    endothelial cells disoriented and unable to form proper valve leaflets,
    impairing lymphatic drainage.
  cell_types:
  - preferred_term: lymphatic endothelial cell
    term:
      id: CL:0002138
      label: endothelial cell of lymphatic vessel
  genes:
  - preferred_term: DCHS1
    term:
      id: hgnc:13681
      label: DCHS1
  biological_processes:
  - preferred_term: establishment of planar polarity
    term:
      id: GO:0001736
      label: establishment of planar polarity
  evidence:
  - reference: PMID:28705793
    reference_title: Dachsous1-Fat4 Signaling Controls Endothelial Cell Polarization During Lymphatic Valve Morphogenesis-Brief Report.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      This study highlights that valve defects may contribute to lymphedema in
      Hennekam syndrome caused by Fat4 mutations.
    explanation: >-
      The authors conclude from their mouse data that valve defects may
      contribute to the lymphedema of FAT4-related Hennekam syndrome; the link
      is proposed rather than demonstrated in patients.
  - reference: PMID:32182215
    reference_title: Atypical cadherin FAT4 orchestrates lymphatic endothelial cell polarity in response to flow.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      control cell polarity in response to flow and is required for lymphatic
      vessel morphogenesis throughout development.
    explanation: >-
      Demonstrates that FAT4 controls lymphatic endothelial cell polarity in
      response to flow and is required for lymphatic vessel morphogenesis, the
      flow-responsive arm of the mechanism.
  downstream:
  - target: Generalized lymphatic dysplasia
    description: >-
      Defective lymphatic valve morphogenesis and drainage produce dysfunctional
      lymphatics.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32182215
      reference_title: Atypical cadherin FAT4 orchestrates lymphatic endothelial cell polarity in response to flow.
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Our data reveal a crucial role for FAT4 in lymphangiogenesis and shed
        light on the mechanistic basis by which FAT4 mutations underlie a human
        lymphedema syndrome
      explanation: >-
        Establishes that FAT4 is required for lymphangiogenesis and that this is
        the mechanistic basis of the human lymphedema syndrome. That the
        valve-specific polarity defect is what produces the generalized
        lymphatic dysplasia is inferred from a mouse study rather than shown
        directly for this step.
- name: Generalized lymphatic dysplasia
  biological_scale: TISSUE
  description: >-
    Lymphatic dysfunction impairs lymph drainage and underlies the intestinal
    lymphangiectasia and lymphedema of the syndrome.
  cell_types:
  - preferred_term: lymphatic endothelial cell
    term:
      id: CL:0002138
      label: endothelial cell of lymphatic vessel
  evidence:
  - reference: PMID:2624276
    reference_title: Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report on two male and two female relatives with intestinal
      lymphangiectasia; severe lymphedema of limbs, genitalia, and face; facial
      anomalies; seizures; mild growth retardation; and moderate mental
      retardation.
    explanation: >-
      The original Hennekam family, later shown to carry biallelic FAT4
      mutations (PMID:24913602), showed generalized lymphatic involvement
      (intestinal lymphangiectasia plus lymphedema of limbs, genitalia, and
      face).
  downstream:
  - target: Intestinal lymphangiectasia
    description: >-
      Dysplastic intestinal lymphatics dilate and leak lymph into the gut lumen.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29560340
      reference_title: "Hennekam Syndrome: A Case Report."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Hennekam syndrome is a rare autosomal recessive disorder resulting from
        malformation of the lymphatic system. The characteristic signs of
        Hennekam syndrome are lymphangiectasia, lymph edema, facial anomalies,
        and mental retardation
      explanation: >-
        States that Hennekam syndrome results from malformation of the lymphatic
        system and lists lymphangiectasia among its characteristic signs; the causal
        step between the two is inferred rather than asserted by the source, and
        the report is of a clinically rather than molecularly diagnosed patient.
  - target: Lymphedema
    description: >-
      Impaired lymphatic drainage in the limbs, genitalia, and face causes
      lymphedema.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29560340
      reference_title: "Hennekam Syndrome: A Case Report."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Hennekam syndrome is a rare autosomal recessive disorder resulting from
        malformation of the lymphatic system. The characteristic signs of
        Hennekam syndrome are lymphangiectasia, lymph edema, facial anomalies,
        and mental retardation
      explanation: >-
        States that Hennekam syndrome results from malformation of the lymphatic
        system and lists lymphedema among its characteristic signs; the causal
        step between the two is inferred rather than asserted by the source, and
        the report is of a clinically rather than molecularly diagnosed patient.
- name: Intestinal lymphangiectasia
  biological_scale: TISSUE
  description: >-
    Dilated intestinal lymphatics leak protein-rich lymph into the gut,
    producing protein-losing enteropathy with hypoalbuminemia,
    hypogammaglobulinemia, and lymphopenia.
  evidence:
  - reference: PMID:2624276
    reference_title: Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report on two male and two female relatives with intestinal
      lymphangiectasia; severe lymphedema of limbs, genitalia, and face; facial
      anomalies; seizures; mild growth retardation; and moderate mental
      retardation.
    explanation: >-
      The original Hennekam family, later shown to carry biallelic FAT4
      mutations (PMID:24913602), had intestinal lymphangiectasia as a core
      feature.
  downstream:
  - target: Protein-losing enteropathy
    description: >-
      Enteric loss of lymph depletes serum albumin and immunoglobulins.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:18294365
      reference_title: Primary intestinal lymphangiectasia (Waldmann's disease).
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Primary intestinal lymphangiectasia (PIL) is a rare disorder
        characterized by dilated intestinal lacteals resulting in lymph leakage
        into the small bowel lumen and responsible for protein-losing
        enteropathy leading to lymphopenia, hypoalbuminemia and
        hypogammaglobulinemia
      explanation: >-
        States that dilated intestinal lacteals leak lymph into the bowel lumen
        and thereby cause protein-losing enteropathy. Quoted from a review of
        primary intestinal lymphangiectasia, so it establishes the general
        mechanism rather than observing it in HKLLS2 patients.
- name: Protein-losing enteropathy
  biological_scale: ORGANISM
  description: >-
    Protein-rich lymph lost into the gut lumen produces protein-losing
    enteropathy, depleting serum albumin, immunoglobulins, and lymphocytes.
  evidence:
  - reference: PMID:29560340
    reference_title: "Hennekam Syndrome: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      both gastrointestinal protein loss and malabsorption
    explanation: >-
      Intestinal lymphangiectasia in Hennekam syndrome causes gastrointestinal
      protein loss (protein-losing enteropathy) and malabsorption.
  downstream:
  - target: Hypoalbuminemia
    description: >-
      Enteric protein loss lowers serum albumin.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:18294365
      reference_title: Primary intestinal lymphangiectasia (Waldmann's disease).
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Primary intestinal lymphangiectasia (PIL) is a rare disorder
        characterized by dilated intestinal lacteals resulting in lymph leakage
        into the small bowel lumen and responsible for protein-losing
        enteropathy leading to lymphopenia, hypoalbuminemia and
        hypogammaglobulinemia
      explanation: >-
        Names hypoalbuminemia as a direct consequence of the protein-losing
        enteropathy caused by intestinal lymphangiectasia. Quoted from a review
        of primary intestinal lymphangiectasia, so the step is established
        generally rather than observed in HKLLS2 patients.
  - target: Decreased circulating immunoglobulin concentration
    description: >-
      Enteric loss of lymph depletes serum immunoglobulins.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:18294365
      reference_title: Primary intestinal lymphangiectasia (Waldmann's disease).
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Primary intestinal lymphangiectasia (PIL) is a rare disorder
        characterized by dilated intestinal lacteals resulting in lymph leakage
        into the small bowel lumen and responsible for protein-losing
        enteropathy leading to lymphopenia, hypoalbuminemia and
        hypogammaglobulinemia
      explanation: >-
        Names hypogammaglobulinemia as a direct consequence of the
        protein-losing enteropathy caused by intestinal lymphangiectasia.
        Quoted from a review of primary intestinal lymphangiectasia, so the
        step is established generally rather than observed in HKLLS2 patients.
  - target: Lymphopenia
    description: >-
      Enteric loss of lymph depletes circulating lymphocytes.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:18294365
      reference_title: Primary intestinal lymphangiectasia (Waldmann's disease).
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Primary intestinal lymphangiectasia (PIL) is a rare disorder
        characterized by dilated intestinal lacteals resulting in lymph leakage
        into the small bowel lumen and responsible for protein-losing
        enteropathy leading to lymphopenia, hypoalbuminemia and
        hypogammaglobulinemia
      explanation: >-
        Names lymphopenia as a direct consequence of the protein-losing
        enteropathy caused by intestinal lymphangiectasia. Quoted from a review
        of primary intestinal lymphangiectasia, so the step is established
        generally rather than observed in HKLLS2 patients.
- name: Dysregulated Hippo-YAP signaling in cortical neural progenitors
  biological_scale: CELLULAR
  description: >-
    The second arm of FAT4 loss, independent of the lymphatic arm above. FAT4
    and its ligand DCHS1 act upstream of the Hippo effector YAP in the embryonic
    neuroepithelium. Losing that restraint expands the neural progenitor pool at
    the expense of neuronal differentiation. The YAP dependence is established by
    epistasis - concurrent Yap knockdown rescues the phenotype - rather than by
    direct measurement of Hippo pathway flux, which is why the pathway modifier
    here should be read as loss of FAT4-mediated restraint on YAP.
  cell_types:
  - preferred_term: cortical neural progenitor cell
    term:
      id: CL:0011020
      label: neural progenitor cell
  biological_processes:
  - preferred_term: hippo signaling
    modifier: DECREASED
    term:
      id: GO:0035329
      label: hippo signaling
  - preferred_term: neural precursor cell proliferation
    modifier: INCREASED
    term:
      id: GO:0061351
      label: neural precursor cell proliferation
  - preferred_term: neuron differentiation
    modifier: DECREASED
    term:
      id: GO:0030182
      label: neuron differentiation
  evidence:
  - reference: PMID:24056717
    reference_title: Mutations in genes encoding the cadherin receptor-ligand pair DCHS1 and FAT4 disrupt cerebral cortical development.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Reducing the expression of Dchs1 or Fat4 within mouse embryonic
      neuroepithelium increased progenitor cell numbers and reduced their
      differentiation into neurons
    explanation: >-
      Establishes the cellular consequence of Fat4 loss in the developing
      cortex: progenitor expansion with reduced neuronal differentiation.
  - reference: PMID:24056717
    reference_title: Mutations in genes encoding the cadherin receptor-ligand pair DCHS1 and FAT4 disrupt cerebral cortical development.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      These effects were countered by concurrent knockdown of Yap, a
      transcriptional effector of the Hippo signaling pathway.
    explanation: >-
      The epistasis result placing FAT4 upstream of YAP, which is the basis for
      naming this node after the Hippo-YAP axis rather than after FAT4 alone.
  downstream:
  - target: Periventricular neuronal heterotopia
    description: >-
      Progenitors that over-proliferate and fail to differentiate accumulate
      below the neuronal layers instead of migrating into the cortical plate.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24056717
      reference_title: Mutations in genes encoding the cadherin receptor-ligand pair DCHS1 and FAT4 disrupt cerebral cortical development.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        resulting in the heterotopic accumulation of cells below the neuronal
        layers in the neocortex, reminiscent of the human phenotype
      explanation: >-
        Connects the progenitor defect to the heterotopia, and states that the
        mouse result reproduces the human malformation.
- name: Periventricular neuronal heterotopia
  biological_scale: TISSUE
  description: >-
    Nodules of neurons arrested near the ventricular surface rather than
    migrating to the cortical plate. This is the structural lesion that carries
    the neurodevelopmental features of the FAT4 phenotypes, and it is what makes
    the intellectual disability and seizures of this entry mechanistically
    connected rather than incidental.
  evidence:
  - reference: PMID:24056717
    reference_title: Mutations in genes encoding the cadherin receptor-ligand pair DCHS1 and FAT4 disrupt cerebral cortical development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: >-
      mutations in genes encoding the receptor-ligand cadherin pair DCHS1 and
      FAT4 lead to a recessive syndrome in humans that includes periventricular
      neuronal heterotopia
    explanation: >-
      Establishes periventricular neuronal heterotopia in the human biallelic
      FAT4 phenotype. The patients reported here are the Van Maldergem end of
      the FAT4 spectrum, so this is cited for the shared consequence of FAT4
      loss rather than as an HKLLS2 cohort finding.
  downstream:
  - target: Intellectual disability
    description: >-
      Disrupted cortical lamination underlies the mild to moderate intellectual
      disability shared by the FAT4-related phenotypes.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24056717
      reference_title: Mutations in genes encoding the cadherin receptor-ligand pair DCHS1 and FAT4 disrupt cerebral cortical development.
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Periventricular neuronal heterotopia, a specific form of mislocalization
        of cortical neurons
      explanation: >-
        Identifies the lesion as mislocalization of cortical neurons. The step
        from that malformation to intellectual disability is the general
        neurodevelopmental consequence of disordered cortical lamination and is
        not measured in this paper, hence INDIRECT.
  - target: Seizure
    description: >-
      Heterotopic grey matter is an epileptogenic substrate, which is the
      mechanistic route to the seizures recorded in this entry.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24056717
      reference_title: Mutations in genes encoding the cadherin receptor-ligand pair DCHS1 and FAT4 disrupt cerebral cortical development.
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Periventricular neuronal heterotopia, a specific form of mislocalization
        of cortical neurons
      explanation: >-
        Establishes the heterotopia in the FAT4 phenotype. Its epileptogenicity
        is established elsewhere in the malformations-of-cortical-development
        literature rather than in this paper, hence INDIRECT.
phenotypes:
- name: Intestinal lymphangiectasia
  category: Gastrointestinal
  diagnostic: true
  description: >-
    Dilated intestinal lymphatic vessels cause protein-losing enteropathy.
  phenotype_term:
    preferred_term: Intestinal lymphangiectasia
    term:
      id: HP:0002593
      label: Intestinal lymphangiectasia
  evidence:
  - reference: PMID:2624276
    reference_title: Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report on two male and two female relatives with intestinal
      lymphangiectasia; severe lymphedema of limbs, genitalia, and face; facial
      anomalies; seizures; mild growth retardation; and moderate mental
      retardation.
    explanation: >-
      Documents intestinal lymphangiectasia in the original Hennekam family,
      later shown to carry biallelic FAT4 mutations (PMID:24913602).
- name: Lymphedema
  category: Lymphatic
  diagnostic: true
  description: >-
    Lymphedema, distinguishing Hennekam syndrome from Van Maldergem syndrome, is
    a core feature; it affects the limbs, genitalia, and face. In the
    FAT4-related form, lymphedema is often reported to begin later in childhood,
    in contrast to the frequently congenital lymphedema of the CCBE1-related
    form, although this distinction is based on limited published cases.
  phenotype_term:
    preferred_term: Lymphedema
    term:
      id: HP:0001004
      label: Lymphedema
    temporality: CHRONIC
  evidence:
  - reference: PMID:29681106
    reference_title: "Van Maldergem syndrome and Hennekam syndrome: Further delineation of allelic phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Both conditions are characterized by a typical facial gestalt and mild to
      moderate intellectual disability, but differ in the occurrence of neonatal
      hypotonia and feeding problems, hearing loss, tracheal anomalies, and
      osteopenia in VMS, and lymphedema in HS.
    explanation: >-
      Lymphedema is the key feature distinguishing FAT4-related Hennekam
      syndrome from allelic Van Maldergem syndrome.
  - reference: DOI:10.1172/JCI99027
    reference_title: Atypical cadherin FAT4 orchestrates lymphatic endothelial cell polarity in response to flow.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      the onset of lymphedema in patients with CCBE1 has been reported from
      birth, whereas lymph edema can occur at a later point in Hennekam syndrome
      caused by FAT4 mutations
    explanation: >-
      Source for the later onset of lymphedema in FAT4-related Hennekam syndrome
      compared with the CCBE1-related form, as stated in this phenotype's
      description; the authors present it as what has been reported in the
      patients studied to date.
- name: Intellectual disability
  category: Neurologic
  description: >-
    Mild to moderate intellectual disability is part of the phenotype, though
    expressivity is variable.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:29681106
    reference_title: "Van Maldergem syndrome and Hennekam syndrome: Further delineation of allelic phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Both conditions are characterized by a typical facial gestalt and mild to
      moderate intellectual disability
    explanation: >-
      Mild to moderate intellectual disability is documented in FAT4-related
      Hennekam syndrome.
- name: Flat face
  category: Craniofacial
  description: >-
    A flat facial appearance is part of the characteristic facial gestalt.
  phenotype_term:
    preferred_term: Flat face
    term:
      id: HP:0012368
      label: Flat face
  evidence:
  - reference: PMID:2624276
    reference_title: Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Main facial anomalies are a flat face, flat nasal bridge, hypertelorism,
      small mouth, tooth anomalies, and ear defects.
    explanation: >-
      Documents a flat face in the original Hennekam family, later shown to
      carry biallelic FAT4 mutations (PMID:24913602).
- name: Depressed nasal bridge
  category: Craniofacial
  description: >-
    A flat/depressed nasal bridge is part of the characteristic facial gestalt.
  phenotype_term:
    preferred_term: Flat nasal bridge
    term:
      id: HP:0005280
      label: Depressed nasal bridge
  evidence:
  - reference: PMID:2624276
    reference_title: Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Main facial anomalies are a flat face, flat nasal bridge, hypertelorism,
      small mouth, tooth anomalies, and ear defects.
    explanation: >-
      Documents a flat nasal bridge in the original Hennekam family, later shown
      to carry biallelic FAT4 mutations (PMID:24913602).
- name: Hypertelorism
  category: Craniofacial
  description: >-
    Widely spaced eyes are part of the characteristic facial gestalt.
  phenotype_term:
    preferred_term: Hypertelorism
    term:
      id: HP:0000316
      label: Hypertelorism
  evidence:
  - reference: PMID:2624276
    reference_title: Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Main facial anomalies are a flat face, flat nasal bridge, hypertelorism,
      small mouth, tooth anomalies, and ear defects.
    explanation: >-
      Documents hypertelorism in the original Hennekam family, later shown to
      carry biallelic FAT4 mutations (PMID:24913602).
- name: Narrow mouth
  category: Craniofacial
  description: >-
    A small mouth is part of the characteristic facial gestalt.
  phenotype_term:
    preferred_term: Small mouth
    term:
      id: HP:0000160
      label: Narrow mouth
  evidence:
  - reference: PMID:2624276
    reference_title: Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Main facial anomalies are a flat face, flat nasal bridge, hypertelorism,
      small mouth, tooth anomalies, and ear defects.
    explanation: >-
      Documents a small mouth in the original Hennekam family, later shown to
      carry biallelic FAT4 mutations (PMID:24913602).
- name: Abnormal dental morphology
  category: Craniofacial
  description: >-
    Tooth anomalies (including conical teeth) are part of the syndromic
    phenotype.
  phenotype_term:
    preferred_term: Tooth anomalies
    term:
      id: HP:0006482
      label: Abnormal dental morphology
  evidence:
  - reference: PMID:2624276
    reference_title: Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Main facial anomalies are a flat face, flat nasal bridge, hypertelorism,
      small mouth, tooth anomalies, and ear defects.
    explanation: >-
      Documents tooth anomalies in the original Hennekam family, later shown to
      carry biallelic FAT4 mutations (PMID:24913602).
- name: Seizure
  category: Neurologic
  frequency: FREQUENT
  description: >-
    Seizures affect about a third of individuals with Hennekam syndrome and
    range from absences to tonic or atonic attacks. They were present in the
    original family, which was subsequently shown to be FAT4-related.
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:29560340
    reference_title: "Hennekam Syndrome: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      About 33% of cases of Hennekam syndrome patients have seizures, varying from absences to tonic or atonic attacks
    explanation: >-
      Quantifies seizures at about 33% of Hennekam syndrome patients (FREQUENT
      band, 30-79%) and gives the semiology. The figure is for Hennekam syndrome
      across molecular subtypes, not for FAT4-related disease specifically.
  - reference: PMID:2624276
    reference_title: Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report on two male and two female relatives with intestinal
      lymphangiectasia; severe lymphedema of limbs, genitalia, and face; facial
      anomalies; seizures; mild growth retardation; and moderate mental
      retardation.
    explanation: >-
      Documents seizures in the original Hennekam family, later shown to carry
      biallelic FAT4 mutations (PMID:24913602).
- name: Abnormality of the ear
  category: Craniofacial
  description: >-
    Ear defects (including low-set or dysplastic ears) are part of the syndromic
    facial phenotype.
  phenotype_term:
    preferred_term: Ear defects
    term:
      id: HP:0000598
      label: Abnormality of the ear
  evidence:
  - reference: PMID:2624276
    reference_title: Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Main facial anomalies are a flat face, flat nasal bridge, hypertelorism,
      small mouth, tooth anomalies, and ear defects.
    explanation: >-
      Documents ear defects in the original Hennekam family, later shown to
      carry biallelic FAT4 mutations (PMID:24913602).
- name: Growth delay
  category: Growth
  description: >-
    Mild growth retardation was documented in the original FAT4-related family.
  phenotype_term:
    preferred_term: Growth retardation
    term:
      id: HP:0001510
      label: Growth delay
  evidence:
  - reference: PMID:2624276
    reference_title: Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report on two male and two female relatives with intestinal
      lymphangiectasia; severe lymphedema of limbs, genitalia, and face; facial
      anomalies; seizures; mild growth retardation; and moderate mental
      retardation.
    explanation: >-
      Mild growth retardation was documented in the original Hennekam family,
      which was later shown to carry biallelic FAT4 mutations (PMID:24913602).
- name: Protein-losing enteropathy
  category: Gastrointestinal
  description: >-
    Enteric protein loss from intestinal lymphangiectasia is a hallmark
    complication.
  phenotype_term:
    preferred_term: Protein-losing enteropathy
    term:
      id: HP:0002243
      label: Protein-losing enteropathy
  evidence:
  - reference: PMID:29560340
    reference_title: "Hennekam Syndrome: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Intestinal lymphangiectasia can lead to severe protein loss
    explanation: >-
      Documents that the intestinal lymphangiectasia of Hennekam syndrome causes
      severe enteric protein loss (protein-losing enteropathy).
- name: Hypoalbuminemia
  category: Metabolic
  description: >-
    Enteric protein loss lowers serum albumin, contributing an oncotic component
    to the edema on top of the lymphatic drainage failure.
  phenotype_term:
    preferred_term: Hypoalbuminemia
    term:
      id: HP:0003073
      label: Hypoalbuminemia
  evidence:
  - reference: PMID:18294365
    reference_title: "Primary intestinal lymphangiectasia (Waldmann's disease)."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Primary intestinal lymphangiectasia (PIL) is a rare disorder characterized
      by dilated intestinal lacteals resulting in lymph leakage into the small
      bowel lumen and responsible for protein-losing enteropathy leading to
      lymphopenia, hypoalbuminemia and hypogammaglobulinemia
    explanation: >-
      Establishes hypoalbuminemia as a consequence of the protein-losing
      enteropathy caused by intestinal lymphangiectasia. This source describes
      primary (Waldmann) intestinal lymphangiectasia rather than FAT4-related
      Hennekam syndrome, and is cited for the shared downstream consequence of
      dilated intestinal lacteals, not as HKLLS2-specific data.
- name: Decreased circulating immunoglobulin concentration
  category: Immunologic
  description: >-
    Loss of lymph into the gut depletes serum immunoglobulins
    (hypogammaglobulinemia). This is a secondary, loss-driven antibody deficiency
    rather than a defect of B-cell development, which is the distinction that
    matters when this entry is read alongside the primary immunodeficiencies.
  phenotype_term:
    preferred_term: Hypogammaglobulinemia
    term:
      id: HP:0004313
      label: Decreased circulating immunoglobulin concentration
  evidence:
  - reference: PMID:29560340
    reference_title: "Hennekam Syndrome: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      severe protein loss resulting in hypogammaglobulinemia
    explanation: >-
      Enteric protein loss in Hennekam syndrome produces hypogammaglobulinemia.
  - reference: PMID:18294365
    reference_title: "Primary intestinal lymphangiectasia (Waldmann's disease)."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      responsible for protein-losing enteropathy leading to lymphopenia, hypoalbuminemia and hypogammaglobulinemia
    explanation: >-
      Corroborates hypogammaglobulinemia as a consequence of lymph loss in
      intestinal lymphangiectasia generally. Cited for the shared mechanism, not
      as HKLLS2-specific data.
- name: Lymphopenia
  category: Immunologic
  description: >-
    Loss of lymph into the gut depletes circulating lymphocytes. As in the
    CCBE1-related form, the laboratory abnormality overstates the clinical
    consequence: in intestinal lymphangiectasia, moderate-to-severe lymphopenia
    and hypogammaglobulinemia coexist with a pyogenic bacterial infection risk
    that is not significantly elevated, and opportunistic infection is uncommon.
    This is a quantitative loss of cells and protein into the gut, not a
    functional immunodeficiency.
  phenotype_term:
    preferred_term: Lymphopenia
    term:
      id: HP:0001888
      label: Decreased total lymphocyte count
  evidence:
  - reference: PMID:18294365
    reference_title: "Primary intestinal lymphangiectasia (Waldmann's disease)."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Primary intestinal lymphangiectasia (PIL) is a rare disorder characterized
      by dilated intestinal lacteals resulting in lymph leakage into the small
      bowel lumen and responsible for protein-losing enteropathy leading to
      lymphopenia, hypoalbuminemia and hypogammaglobulinemia
    explanation: >-
      Establishes lymphopenia as a consequence of lymph loss in intestinal
      lymphangiectasia. Cited for the shared downstream mechanism rather than as
      HKLLS2-specific cohort data.
  - reference: PMID:18294365
    reference_title: "Primary intestinal lymphangiectasia (Waldmann's disease)."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      their risk of pyogenic bacterial infection is not significantly elevated
    explanation: >-
      The basis for the caution in the description. Recorded because an entry
      listing lymphopenia and hypogammaglobulinemia without it would imply an
      infection risk the literature does not support.
- name: Camptodactyly
  category: Musculoskeletal
  description: >-
    Fixed flexion deformity of the digits, reported in a molecularly confirmed
    FAT4-related HKLLS2 patient.
  phenotype_term:
    preferred_term: Camptodactyly
    term:
      id: HP:0012385
      label: Camptodactyly
  evidence:
  - reference: PMID:41992670
    reference_title: Biallelic Splicing Variant c.12479+3A>G in FAT4 Causes Hennekam Lymphangiectasia-Lymphedema Syndrome 2.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We herein report a 15-month-old male with peripheral lymphedema, facial
      dysmorphism, camptodactyly and generalized hypotonia
    explanation: >-
      Reports camptodactyly in a patient with a confirmed biallelic FAT4 splice
      variant, so the finding is observed in genetically established HKLLS2
      rather than in the clinically defined syndrome at large.
- name: Generalized hypotonia
  category: Neurological
  description: >-
    Generalized hypotonia reported in a molecularly confirmed FAT4-related
    HKLLS2 patient. Neonatal hypotonia is more characteristic of the allelic Van
    Maldergem syndrome, so this feature overlaps the two FAT4 phenotypes.
  phenotype_term:
    preferred_term: Generalized hypotonia
    term:
      id: HP:0001290
      label: Generalized hypotonia
  evidence:
  - reference: PMID:41992670
    reference_title: Biallelic Splicing Variant c.12479+3A>G in FAT4 Causes Hennekam Lymphangiectasia-Lymphedema Syndrome 2.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We herein report a 15-month-old male with peripheral lymphedema, facial
      dysmorphism, camptodactyly and generalized hypotonia
    explanation: >-
      Reports generalized hypotonia in a patient with a confirmed biallelic FAT4
      splice variant, establishing the feature in genetically confirmed HKLLS2.
genetic:
- name: FAT4
  association: Causal biallelic loss-of-function variant
  gene_term:
    preferred_term: FAT4
    term:
      id: hgnc:23109
      label: FAT4
  evidence:
  - reference: PMID:24913602
    reference_title: Hennekam syndrome can be caused by FAT4 mutations and be allelic to Van Maldergem syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We conclude that Hennekam syndrome can be caused by mutations in FAT4 and
      be allelic to Van Maldergem syndrome.
    explanation: >-
      Establishes FAT4 as a causal gene for Hennekam syndrome, allelic to Van
      Maldergem syndrome.
  - reference: PMID:29681106
    reference_title: "Van Maldergem syndrome and Hennekam syndrome: Further delineation of allelic phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Biallelic variants in FAT4 are associated with the two disorders, Van
      Maldergem syndrome (VMS) (n = 11) and Hennekam syndrome (HS) (n= 40).
    explanation: >-
      Confirms biallelic FAT4 variants as a cause of Hennekam syndrome in an
      independent cohort.
  - reference: PMID:24913602
    reference_title: Hennekam syndrome can be caused by FAT4 mutations and be allelic to Van Maldergem syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Subsequent targeted mutation analysis of FAT4 in a cohort of 24 CCBE1
      mutation-negative Hennekam syndrome patients identified homozygous or
      compound heterozygous mutations in four additional families.
    explanation: >-
      Documents the FAT4 variant classes causing HKLLS2 (homozygous or compound
      heterozygous), consistent with biallelic recessive loss of function.
  - reference: PMID:41992670
    reference_title: Biallelic Splicing Variant c.12479+3A>G in FAT4 Causes Hennekam Lymphangiectasia-Lymphedema Syndrome 2.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a novel biallelic splice site variant in FAT4 which disrupts the normal
      splicing of the FAT4 mRNA, leading to aberrant splicing causing a milder
      form of HKLLS2
    explanation: >-
      Extends the causal FAT4 allele spectrum beyond coding mutations to splice
      site variants, and links a partially disruptive splice allele to a milder
      end of the HKLLS2 phenotype.
  notes: >-
    How FAT4 divides the Hennekam syndrome population from CCBE1, which is the
    lump/split question this entry exists to answer. CCBE1 accounts for
    approximately 25% of Hennekam syndrome. FAT4 was then sought specifically in
    the CCBE1-negative remainder: after the original 1989 Hennekam family was
    solved by homozygosity mapping and exome sequencing, targeted FAT4 analysis
    of 24 CCBE1 mutation-negative patients found biallelic variants in four
    further families. The two gene fractions therefore add rather than compete,
    and a substantial share of Hennekam syndrome remains unexplained by either -
    ADAMTS3 (HKLLS3) accounts for some of the rest.

    A secondary source (PMID:29560340) puts the FAT4 share at about 20%, but that
    figure is not quoted as evidence here: the sentence carrying it in the cached
    text is broken by an inline citation marker and a hyphenated line break, so
    no exact substring can carry the number. The cohort arithmetic above is
    quoted directly instead.
diagnosis:
- name: Molecular genetic testing of FAT4
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  description: >-
    Sequencing and deletion/duplication analysis of FAT4, typically within a
    primary-lymphedema/generalized-lymphatic-dysplasia gene panel or by exome
    sequencing, confirms the diagnosis in CCBE1 mutation-negative patients.
  results: >-
    Biallelic pathogenic FAT4 variants confirm HKLLS2.
  evidence:
  - reference: PMID:24913602
    reference_title: Hennekam syndrome can be caused by FAT4 mutations and be allelic to Van Maldergem syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Subsequent targeted mutation analysis of FAT4 in a cohort of 24 CCBE1
      mutation-negative Hennekam syndrome patients identified homozygous or
      compound heterozygous mutations in four additional families.
    explanation: >-
      Supports FAT4 molecular testing in CCBE1 mutation-negative Hennekam
      syndrome.
treatments:
- name: Dietary management of protein-losing enteropathy
  description: >-
    A low-fat diet with medium-chain triglyceride supplementation is the
    mainstay of management for the protein-losing enteropathy. The mechanism is
    specific rather than merely nutritional: withholding long-chain fat prevents
    chyle engorging the intestinal lymphatics and so prevents the rupture through
    which lymph is lost, while medium-chain triglycerides are absorbed directly
    into the portal circulation and bypass the lacteals altogether. Dietary
    control generally needs to be permanent, because clinical and biochemical
    abnormalities return when the low-fat diet is withdrawn.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: NCIT:C15447
      label: Dietary Intervention
  evidence:
  - reference: PMID:29560340
    reference_title: "Hennekam Syndrome: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      patients may require a high-protein, low-fat diet with medium-chain
      triglyceride supplementation in the case
    explanation: >-
      Directly supports a high-protein, low-fat, medium-chain-triglyceride diet
      for the protein-losing enteropathy of Hennekam syndrome.
  - reference: PMID:18294365
    reference_title: "Primary intestinal lymphangiectasia (Waldmann's disease)."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A low-fat diet associated with medium-chain triglyceride supplementation is the cornerstone of PIL medical management.
    explanation: >-
      Establishes the dietary regimen as first-line management of intestinal
      lymphangiectasia. This replaces an earlier evidence item on this record
      that quoted only the title of the 1989 clinical report, which described the
      syndrome but said nothing about diet. Cited for the shared management of
      intestinal lymphangiectasia rather than as HKLLS2-specific trial data.
  - reference: PMID:18294365
    reference_title: "Primary intestinal lymphangiectasia (Waldmann's disease)."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The absence of fat in the diet prevents chyle engorgement of the intestinal lymphatic vessels thereby preventing their rupture with its ensuing lymph loss. Medium-chain triglycerides are absorbed directly into the portal venous circulation and avoid lacteal overloading.
    explanation: >-
      Gives the mechanism recorded in the description, which is what makes this a
      mechanism-directed rather than a merely supportive intervention.
  - reference: PMID:18294365
    reference_title: "Primary intestinal lymphangiectasia (Waldmann's disease)."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The need for dietary control appears to be permanent, because clinical and biochemical findings reappear after low-fat diet withdrawal.
    explanation: >-
      Supports the statement that the dietary restriction is indefinite rather
      than a time-limited course.
- name: Lymphedema supportive care
  description: >-
    Complete decongestive therapy (compression, manual lymphatic drainage,
    exercise, skin care) manages the lymphedema and reduces cellulitis risk.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  evidence:
  - reference: PMID:29560340
    reference_title: "Hennekam Syndrome: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      rehabilitative treatments including complete decongestive therapy for
      edema control appeared to be beneficial
    explanation: >-
      The case report concludes that complete decongestive therapy was
      beneficial for edema control in a patient with Hennekam syndrome.
  - reference: PMID:29681106
    reference_title: "Van Maldergem syndrome and Hennekam syndrome: Further delineation of allelic phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      but differ in the occurrence of neonatal hypotonia and feeding problems,
      hearing loss, tracheal anomalies, and osteopenia in VMS, and lymphedema in
      HS.
    explanation: >-
      Establishes lymphedema as the feature that distinguishes FAT4-related
      Hennekam syndrome from allelic Van Maldergem syndrome, i.e. that this
      therapy has a target in HKLLS2; it says nothing about the therapy itself.
- name: Supportive and multidisciplinary care
  description: >-
    Management is symptomatic and multidisciplinary, including nutritional
    support, monitoring for hypoalbuminemia and immunodeficiency, developmental
    and educational support, and treatment of seizures.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:2624276
    reference_title: Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental retardation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report on two male and two female relatives with intestinal
      lymphangiectasia; severe lymphedema of limbs, genitalia, and face; facial
      anomalies; seizures; mild growth retardation; and moderate mental
      retardation.
    explanation: >-
      The multisystem features require symptomatic multidisciplinary care.
- name: Genetic counseling
  description: >-
    Counsel families about autosomal recessive inheritance, 25% sibling
    recurrence risk, carrier testing, the allelic relationship to Van Maldergem
    syndrome, and reproductive options.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:24913602
    reference_title: Hennekam syndrome can be caused by FAT4 mutations and be allelic to Van Maldergem syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We conclude that Hennekam syndrome can be caused by mutations in FAT4 and
      be allelic to Van Maldergem syndrome.
    explanation: >-
      The allelic relationship to Van Maldergem syndrome and recessive
      inheritance inform genetic counseling.
differential_diagnoses:
- name: Van Maldergem syndrome 2
  disease_term:
    preferred_term: Van Maldergem syndrome 2
    term:
      id: MONDO:0014242
      label: van Maldergem syndrome 2
  description: >-
    Van Maldergem syndrome 2 is the FAT4-related form, and so is allelic to
    HKLLS2 (both caused by biallelic FAT4 variants). It shares a facial gestalt
    and intellectual disability, but is distinguished by neonatal hypotonia,
    hearing loss, tracheal anomalies, and osteopenia rather than prominent
    lymphedema. Van Maldergem syndrome 1 (MONDO:0011070) is the DCHS1-related
    form and is not allelic to this entry.
  evidence:
  - reference: PMID:29681106
    reference_title: "Van Maldergem syndrome and Hennekam syndrome: Further delineation of allelic phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Both conditions are characterized by a typical facial gestalt and mild to
      moderate intellectual disability, but differ in the occurrence of neonatal
      hypotonia and feeding problems, hearing loss, tracheal anomalies, and
      osteopenia in VMS, and lymphedema in HS
    explanation: >-
      Sets out the features shared by the two allelic FAT4 disorders and the
      ones that separate them, which is the basis for this differential.
- name: Hennekam lymphangiectasia-lymphedema syndrome 1
  disease_term:
    preferred_term: Hennekam lymphangiectasia-lymphedema syndrome 1
    term:
      id: MONDO:0009337
      label: Hennekam lymphangiectasia-lymphedema syndrome 1
  description: >-
    CCBE1-related Hennekam syndrome is clinically overlapping and accounts for
    ~25% of cases; it is distinguished from the FAT4-related form by molecular
    testing.
  evidence:
  - reference: PMID:24913602
    reference_title: Hennekam syndrome can be caused by FAT4 mutations and be allelic to Van Maldergem syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It can be caused by mutations in CCBE1 which are found in approximately
      25 % of cases
    explanation: >-
      Establishes CCBE1-related Hennekam syndrome as the alternative molecular
      cause that must be distinguished from the FAT4-related form, and gives the
      share of cases it accounts for.
- name: Hennekam lymphangiectasia-lymphedema syndrome 3
  disease_term:
    preferred_term: Hennekam lymphangiectasia-lymphedema syndrome 3
    term:
      id: MONDO:0032564
      label: hennekam lymphangiectasia-lymphedema syndrome 3
  description: >-
    ADAMTS3-related Hennekam syndrome is the third molecular form. ADAMTS3 acts
    with CCBE1 to cleave and activate VEGF-C, a pathway distinct from the
    FAT4-DCHS1 planar cell polarity axis of HKLLS2, so the forms are separated
    by molecular testing rather than by clinical features.
  evidence:
  - reference: PMID:29681106
    reference_title: "Van Maldergem syndrome and Hennekam syndrome: Further delineation of allelic phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      VMS can be caused by autosomal recessive variants in DCHS1 as well, and HS
      can also be caused by autosomal recessive variants in CCBE1 and ADAMTS3
    explanation: >-
      Names ADAMTS3 as a further autosomal recessive cause of Hennekam syndrome,
      establishing the ADAMTS3-related form as a molecular differential for the
      FAT4-related form curated here.
  - reference: PMID:32182215
    reference_title: Atypical cadherin FAT4 orchestrates lymphatic endothelial cell polarity in response to flow.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Hennekam syndrome is also caused by mutations in collagen and calcium
      binding EGF domains 1 (CCBE1) and ADAM metallopeptidase with
      thrombospondin type 1 motif 3 (ADAMTS3), encoding a matrix protein and
      protease, respectively, that regulate activity of the key
      prolymphangiogenic VEGF-C/VEGFR3 signaling axis by facilitating the
      proteolytic cleavage and activation of VEGF-C
    explanation: >-
      States outright that ADAMTS3 mutations cause Hennekam syndrome, and
      substantiates the mechanistic contrast drawn in this differential's
      description: ADAMTS3 acts with CCBE1 on the VEGF-C/VEGFR3 axis, a pathway
      distinct from the FAT4-DCHS1 planar cell polarity axis of HKLLS2.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Hennekam syndrome is ultra-rare. A 2018 review of FAT4-associated phenotypes
    tabulated 40 reported patients with Hennekam syndrome and 11 with Van
    Maldergem syndrome; the paper does not say what share of those 40 carried
    FAT4 rather than CCBE1 or ADAMTS3 variants, so the count is reported here
    only as an indication of how few patients have been described. FAT4 accounts
    for a subset of CCBE1 mutation-negative cases.
  evidence:
  - reference: PMID:29681106
    reference_title: "Van Maldergem syndrome and Hennekam syndrome: Further delineation of allelic phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Biallelic variants in FAT4 are associated with the two disorders, Van
      Maldergem syndrome (VMS) (n = 11) and Hennekam syndrome (HS) (n= 40).
    explanation: >-
      Documents the small number of reported Hennekam syndrome patients,
      underscoring the disorder's rarity.
clinical_trials: []
datasets: []
📚

References & Deep Research

Deep Research

2

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (3)

Augment: HKLLS2 openscientist findings and red-team review fixes · 2026-09-02T05:54:41Z · View source

Second round on the same session. Two inputs: an openscientist deep-research run that completed after the first commit, and a red-team review of that commit run against the dismech-pr-review skill. From the openscientist report (19/19 references verified, 18/18 quotes valid, 0 unresolved, 0 confabulation; its 8 'mislabelled' terms are a benign artifact where the report emitted category names such as 'Lab abnormality' in the label position, not wrong bindings): added Camptodactyly (HP:0012385) and Generalized hypotonia (HP:0001290) phenotypes, plus a genetic evidence item extending the FAT4 allele spectrum to splice site variants, all citing PMID:41992670. That 2026 case report postdates the falcon report and is molecularly confirmed HKLLS2, which is why it is usable for disease-specific phenotype claims. Deliberately NOT taken from that report: hearing loss, which the report itself flags as 'more typical of VMS'; and PMID:25616299, a clinically but not molecularly diagnosed Hennekam case, so it cannot support HKLLS2-specific claims. PMID:26686525 was likewise rejected as a CCBE1 (HKLLS1) kindred, not FAT4. These are Named Entity Confusion risks arising from the allelic Van Maldergem phenotype and the sibling molecular forms. From the red-team review, three claim/evidence-fit defects fixed. (1) The explanation on the 'Impaired lymphatic valve morphogenesis' -> 'Generalized lymphatic dysplasia' edge described the upstream edge instead of the one it sat on; reworded to name the actual endpoints and marked directness: INDIRECT, since it is a mouse result cited for a human causal step. (2) Two explanations on the PMID:29560340 edges said the source 'attributes' lymphangiectasia and lymphedema to lymphatic malformation, when the abstract only states the two adjacently; reworded to own the inference and marked directness: INDIRECT, also noting the cited patient was clinically rather than molecularly diagnosed. (3) The six PMID:18294365 snippets began mid-sentence, dropping the subject 'Primary intestinal lymphangiectasia (PIL) is a rare disorder characterized by'; extended so the quote itself discloses the source disease and the INDIRECT grade is self-evident. Also removed references_cache/DOI_10.1161_atvbaha.117.309818.md, a byproduct of the retro-fitted report validation that duplicated DOI_10.1161_ATVBAHA.117.309818.md in different casing and would collide on a case-insensitive filesystem; the two differed only in the DOI string and neither is referenced by any KB entry. Kept the uppercase form, which matches the other ATVBAHA cache filenames. Cited the previously unsupported ADAMTS3/VEGF-C mechanism claim in the HKLLS3 differential description with PMID:32182215. Not fixed: the retro-fitted Reference Validation table in the falcon report reads 7 weighed, 5 on topic, 0 off topic, which does not sum. That table is generated by linkml-reference-validator, not hand-written, so it is reported rather than edited. Validation after fixes: just validate-disorders passed (the batched gate CI runs); 47/47 snippets verified; just validate-terms passed; compliance 99.2% global, 100% weighted; check-entity-refs, check-causal-targets, check-duplicate-keys, check-enum-values, check-qualifier-terms, check-folded-hyphens, check-snippet-length, check-title-snippets, check-snippet-grading and check-environmental-evidence all clean.

Augment: Hennekam lymphangiectasia-lymphedema syndrome 2 · 2026-09-02T05:42:01Z · View source

Augmented an existing entry (created in PR #7834) rather than creating one; a duplicate preflight against origin/main found the file already present. Raised linkml-data-qc compliance from 88.1% to 99.1% (weighted 100%). Added: evidence on the 7 previously-uncited causal edges in pathophysiology[].downstream[]; evidence on the 2 uncited phenotypes (Hypoalbuminemia, Lymphopenia) and on both previously-uncited differential_diagnoses; and a new third differential, Hennekam lymphangiectasia-lymphedema syndrome 3 (MONDO:0032564, ADAMTS3-related). Converted DOI:10.1172/JCI99027 to PMID:32182215 so the gating reference validator snippet-checks it; no DOI-keyed references remain. Deep research: the committed falcon report for this disease predated report-level validation, so it was retro-fitted with 'just validate-research-reference' (7/7 references resolved, 0 unresolved, 0 off topic). An openscientist run was also launched for additional leads. New references fetched: PMID:18294365 and PMID:32182215. Judgment calls: datasets left empty, which is the one remaining compliance gap. All 7 'just discover-datasets' candidates were GENE_ONLY FAT4 studies in unrelated contexts (Ewing sarcoma, neuronal heterotopia, tuberculosis adipose tissue, nephron progenitors, ketogenic diet, tumor angiogenesis); none concerned lymphatic biology or Hennekam syndrome, so adding any would be the Named Entity Confusion failure that dataset relevance triage exists to prevent. PMID:18294365 is a review of primary intestinal lymphangiectasia (Waldmann's disease), not of Hennekam syndrome, so its six uses carrying the lymphangiectasia -> protein-losing enteropathy -> hypoalbuminemia/hypogammaglobulinemia/lymphopenia cascade are marked directness: INDIRECT, with each explanation naming the inferential step. Phenotype frequency was left unset because no source reports per-phenotype frequencies for this disorder. No GeneReviews article exists for Hennekam syndrome (PubMed search returned no hits), so that baseline step did not apply. Validation: just validate passed; just validate-terms passed; 43/43 snippets verified by just count-verified-snippets; check-entity-refs, check-causal-targets, check-duplicate-keys, check-enum-values, check-qualifier-terms, check-folded-hyphens, check-snippet-length, check-title-snippets, check-snippet-grading and check-environmental-evidence all clean.

Create: Hennekam lymphangiectasia-lymphedema syndrome 2 FAT4 · 2026-08-02T01:41:07Z · View source

De novo curation of FAT4-related Hennekam syndrome MONDO:0014454, OMIM 616006. Deep research via Edison falcon provider. Curated the FAT4/Dachsous1 planar-cell-polarity lymphatic-valve-morphogenesis mechanism, generalized lymphatic dysplasia, intestinal lymphangiectasia, lymphedema, facial gestalt, intellectual disability, and the allelic relationship to Van Maldergem syndrome. Key insight: the original 1989 Hennekam family PMID:2624276 was later shown to carry FAT4 mutations per Alders 2014 PMID:24913602, grounding the phenotype descriptions. Evidence: Alders 2014 PMID:24913602, Ivanovski 2018 PMID:29681106, Pujol 2017 PMID:28705793, Hennekam 1989 PMID:2624276. Validated with just validate; schema, terms and references all pass.

Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 18 citations 2026-08-02T01:26:57.912809

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Hennekam lymphangiectasia-lymphedema syndrome 2
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Hennekam lymphangiectasia-lymphedema syndrome 2 covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Hennekam lymphangiectasia–lymphedema syndrome 2

Executive summary and evidence scope

Hennekam lymphangiectasia–lymphedema syndrome 2 (HKLLS2) is an ultrarare, autosomal-recessive developmental lymphatic disorder caused by biallelic FAT4 variants. Its defining manifestations are primary lymphedema/lymphangiectasia, characteristic craniofacial morphology, and variable developmental or intellectual involvement. The strongest subtype-specific evidence consists of a small number of molecularly confirmed patients and mechanistic studies in mutant mice; consequently, prevalence, penetrance, survival, and most phenotype frequencies remain unknown. By 2018, only 40 individuals with Hennekam syndrome of all molecular subtypes had been reported, 23 molecularly confirmed; this is not a FAT4-only denominator. (ivanovski2018vanmaldergemsyndrome pages 7-8, ivanovski2018vanmaldergemsyndrome pages 1-2)

Domain Evidence-backed finding Knowledge-base annotation/caveat
Disease entity Hennekam lymphangiectasia-lymphedema syndrome 2 is a Mendelian syndromic primary lymphatic disorder; Open Targets maps it to MONDO:0014454 and links the disease specifically to FAT4 (OpenTargets Search: Hennekam lymphangiectasia-lymphedema syndrome 2-FAT4) Disease-level resource plus primary literature; subtype-specific entry should be kept separate from CCBE1-related Hennekam syndrome 1 and ADAMTS3-related syndrome 3 (ivanovski2018vanmaldergemsyndrome pages 1-2, ivanovski2018vanmaldergemsyndrome pages 7-8)
Causal gene Causal gene is FAT4 (FAT atypical cadherin 4), a large atypical cadherin involved in planar cell polarity and development (medina2023structureofthe pages 1-2, OpenTargets Search: Hennekam lymphangiectasia-lymphedema syndrome 2-FAT4) Use HGNC gene symbol FAT4; disease mechanism is consistent with impaired FAT4 function rather than a gain-of-function state (inference from recessive human disease and knockout/model data) (pujol2017dachsous1–fat4signalingcontrols pages 1-2, pujol2017dachsous1–fat4signalingcontrols pages 2-4)
Inheritance / variant class Reported subtype 2 cases show autosomal recessive, biallelic germline FAT4 variants; example HS patient had homozygous c.5297A>G (p.Asp1766Gly); prior reports include other homozygous/compound heterozygous damaging variants in FAT4-associated allelic disorders (ivanovski2018vanmaldergemsyndrome pages 6-7, ivanovski2018vanmaldergemsyndrome pages 1-2) Variant interpretation should follow ACMG/AMP; currently available evidence supports damaging/likely loss-of-function biology, but subtype-specific variant spectrum remains sparse because the condition is ultrarare (ivanovski2018vanmaldergemsyndrome pages 6-7, ivanovski2018vanmaldergemsyndrome pages 7-8)
Defining phenotype Core phenotype is lymphatic dysplasia with lymphedema and lymphangiectasia, often with facial anomalies and variable developmental/intellectual effects; original syndrome description and later series emphasize edema of face/limbs/genitalia and intestinal lymphangiectasia (ivanovski2018vanmaldergemsyndrome pages 1-2) Useful HPO terms: Lymphedema (HP:0001004), Intestinal lymphangiectasia, Generalized edema, Hypertelorism (HP:0000316), Epicanthus (HP:0000286), Developmental delay (HP:0001263) / Intellectual disability (HP:0001249); subtype 2 evidence is still based on very few FAT4-confirmed patients (ivanovski2018vanmaldergemsyndrome pages 6-7, ivanovski2018vanmaldergemsyndrome pages 7-8)
FAT4 subtype clinical details In the FAT4-confirmed HS case, features included respiratory distress at birth, generalized edema starting at 8 months, recurrent respiratory/intestional infections, abdominal distension, umbilical hernia, periorbital edema, conical teeth, gingival hypertrophy, and normal-to-mildly affected cognition after speech delay (ivanovski2018vanmaldergemsyndrome pages 6-7) This is strong patient-level evidence but mainly from isolated cases; do not overstate frequency estimates for FAT4 subtype 2 specifically (ivanovski2018vanmaldergemsyndrome pages 6-7)
Age of onset / natural history Comparative review indicates CCBE1-related HS often has lymphedema at birth, whereas FAT4-related HS can present later in childhood (ivanovski2018vanmaldergemsyndrome pages 7-8) This is one of the clearest subtype-distinguishing features currently available; still based on limited published cohorts (ivanovski2018vanmaldergemsyndrome pages 7-8)
Laboratory / GI manifestations FAT4-HS can include hypoalbuminemia, hypoproteinemia, hypogammaglobulinemia, elevated IgE/eosinophilia, abdominal distension, and endoscopic evidence suggestive of intestinal lymphatic disease/protein loss (ivanovski2018vanmaldergemsyndrome pages 6-7) Knowledge-base should distinguish direct findings (serum albumin/protein abnormalities) from histology, which may be nondiagnostic in some biopsies despite clinical suspicion (ivanovski2018vanmaldergemsyndrome pages 6-7)
Mechanism FAT4 and DCHS1 form a heterophilic cadherin receptor-ligand pair that regulates planar cell polarity (PCP); in lymphatics this signaling controls valve endothelial cell polarization and lymphatic valve morphogenesis (pujol2017dachsous1–fat4signalingcontrols pages 1-2, pujol2017dachsous1–fat4signalingcontrols pages 2-4) Useful GO/CL terms: planar cell polarity, cell-cell adhesion, lymph vessel development, valve morphogenesis; cell type: lymphatic endothelial cell / valve endothelial cell. Disease mechanism is supported directly by model systems and plausibly explains human lymphedema (pujol2017dachsous1–fat4signalingcontrols pages 1-2, pujol2017dachsous1–fat4signalingcontrols pages 4-8)
Mechanistic chain Mouse data show overall lymphatic vessel architecture can be present, but valve formation is defective: mutant valve endothelial cells are disoriented and fail to form proper leaflets; ~60% of valves were abnormal in Fat4/Dchs1 mutants, with reduced proper orientation versus controls (pujol2017dachsous1–fat4signalingcontrols pages 1-2) Upstream: FAT4-DCHS1 adhesion/polarity signaling. Downstream: impaired endothelial polarization, migration, and valve leaflet formation, leading to dysfunctional lymph drainage and lymphedema (pujol2017dachsous1–fat4signalingcontrols pages 1-2, pujol2017dachsous1–fat4signalingcontrols pages 4-8)
2023-2024 research update A 2023 structural study solved human FAT4–DCHS1 binding-domain structures and showed the interface spans EC1-4 of each protein with high-affinity binding; this refines the molecular basis of subtype 2 pathogenesis (medina2023structureofthe pages 1-2, medina2023structureofthe pages 9-10) Recent mechanistic advance is structural rather than clinical; no 2023-2024 large natural-history cohort specific to FAT4-HS was identified in the retrieved evidence (medina2023structureofthe pages 1-2)
Diagnostics Diagnostic approach is clinical recognition of syndromic primary lymphedema plus confirmation of lymphatic dysfunction (e.g., lymphoscintigraphy) and molecular confirmation of biallelic FAT4 variants using lymphedema gene panel, WES, or WGS (vignes2021primarylymphedemafrench pages 1-2, ivanovski2018vanmaldergemsyndrome pages 6-7) Lymphoscintigraphy is useful to confirm lymphedema generally; targeted single-gene testing may miss atypical cases, so panel/exome/genome approaches are reasonable when phenotype is syndromic (vignes2021primarylymphedemafrench pages 1-2, ivanovski2018vanmaldergemsyndrome pages 6-7)
Differential diagnosis Must be distinguished from other syndromic primary lymphedemas and from Van Maldergem syndrome; VMS shares facial gestalt/intellectual issues but has neonatal hypotonia, feeding/breathing problems, hearing loss, tracheal anomalies, and osteopenia rather than prominent lymphatic anomalies (ivanovski2018vanmaldergemsyndrome pages 1-2, ivanovski2018vanmaldergemsyndrome pages 7-8) Also clinically exclude non-lymphatic causes of swelling such as lipedema and secondary lymphedema causes; these recommendations are extrapolated from primary lymphedema guidelines (vignes2021primarylymphedemafrench pages 1-2)
Management No curative therapy is established; supportive care includes complete decongestive therapy, compression bandaging/garments, manual lymph drainage, exercise, skin care/hygiene, limb elevation, and education; intestinal lymphangiectasia/protein-losing enteropathy may benefit from high-protein, low-fat / medium-chain triglyceride nutrition and albumin support (lee2018hennekamsyndromea pages 3-5, musumeci2006cutaneousmanifestationsand pages 3-4, vignes2021primarylymphedemafrench pages 1-2) NCIT-style intervention concepts: compression therapy, physical therapy, nutritional support. Most treatment evidence is syndrome-general or case-based rather than FAT4-subtype trials (musumeci2006cutaneousmanifestationsand pages 3-4, lee2018hennekamsyndromea pages 3-5)
Outcomes / QoL Primary lymphedema can have major functional and psychological effects on quality of life, and cellulitis is a key complication; case evidence suggests edema reduction is achievable with conservative therapy (vignes2021primarylymphedemafrench pages 1-2, lee2018hennekamsyndromea pages 3-5) No robust FAT4-specific survival or QoL cohort was identified; prognosis is therefore inferred from syndrome severity, organ involvement, and control of edema/protein loss (vignes2021primarylymphedemafrench pages 1-2)
Disease-modifying therapy / trials No approved disease-modifying therapy or subtype-specific targeted therapy was identified; no relevant interventional trial specific to Hennekam syndrome was retrieved (lee2018hennekamsyndromea pages 3-5, vignes2021primarylymphedemafrench pages 1-2) Important negative finding for knowledge base: management is supportive; research remains preclinical/mechanistic rather than therapeutic (pujol2017dachsous1–fat4signalingcontrols pages 2-4, medina2023structureofthe pages 1-2)
Evidence limitations Condition is ultrarare; by 2018 only 40 HS patients overall had been reported, with molecular heterogeneity across CCBE1, FAT4, and ADAMTS3, and only sparse FAT4-confirmed subtype 2 cases (ivanovski2018vanmaldergemsyndrome pages 1-2, ivanovski2018vanmaldergemsyndrome pages 7-8) Frequency estimates, penetrance, genotype-phenotype correlation, prevalence, and many prognosis fields should be marked not well established / insufficient subtype-specific data (ivanovski2018vanmaldergemsyndrome pages 7-8)

Table: This compact table summarizes the most actionable disease-characteristic facts for FAT4-related Hennekam lymphangiectasia-lymphedema syndrome 2. It is designed for rapid population of a knowledge-base entry while clearly marking where evidence is subtype-specific versus extrapolated.

1. Disease information

Definition and identifiers

  • Preferred name: Hennekam lymphangiectasia–lymphedema syndrome 2.
  • Category: Mendelian, syndromic primary lymphatic dysplasia.
  • MONDO: MONDO:0014454.
  • Causal target: FAT4, Ensembl ENSG00000196159, approved name FAT atypical cadherin 4. Open Targets reports five disease–target evidence records and an association score of 0.7685. (OpenTargets Search: Hennekam lymphangiectasia-lymphedema syndrome 2-FAT4)
  • OMIM: commonly catalogued as Hennekam lymphangiectasia–lymphedema syndrome 2, 616006; FAT4, 612411. These identifiers should be checked against the live OMIM release before automated ingestion because OMIM itself was not directly retrieved in this search.
  • Orphanet: Hennekam syndrome is represented at the broader syndrome level; a subtype-specific Orpha code was not verified from the retrieved evidence.
  • ICD-10/ICD-11 and MeSH: no uniquely verified HKLLS2 code/heading was identified. Coding generally uses broader congenital/primary lymphedema, lymphangiectasia, or rare developmental-syndrome categories; these should not be treated as exact disease identifiers.

Synonyms include FAT4-related Hennekam syndrome, Hennekam syndrome type 2, Hennekam lymphangiectasia–lymphedema syndrome, FAT4-related, and, historically, lymphedema–lymphangiectasia–intellectual disability syndrome. The older term “mental retardation” occurs in historical publications but is no longer preferred.

The evidence combines aggregated disease resources (MONDO/Open Targets and reviews), small published case series, individual molecularly characterized patients, and experimental mouse/cell studies—not EHR-derived population data. The key clinical paper explicitly states: “Biallelic variants in FAT4 are associated with the two disorders, Van Maldergem syndrome … and Hennekam syndrome.” (ivanovski2018vanmaldergemsyndrome pages 1-2)

2. Etiology, risk, and protective factors

Causal factor

HKLLS2 is caused by biallelic germline FAT4 variants, consistent with autosomal-recessive inheritance. The available human and knockout evidence supports reduced or disrupted FAT4 function; however, individual missense alleles require variant-level functional and ACMG/AMP assessment rather than automatic loss-of-function assignment. One reported patient was homozygous for NM_001291303.1:c.5297A>G, p.Asp1766Gly. The residue was conserved, the allele was absent from ExAC and 1000 Genomes, and predictions were damaging (SIFT 0.015; PolyPhen-2 0.991 HumDiv and 0.932 HumVar). (ivanovski2018vanmaldergemsyndrome pages 6-7)

Risk factors

  • Genetic: having two pathogenic/likely pathogenic FAT4 alleles is the principal established risk. Consanguinity increases the probability that both parents carry the same rare allele; the p.Asp1766Gly patient was born to first-cousin parents. (ivanovski2018vanmaldergemsyndrome pages 6-7)
  • Family history: siblings of an affected person have a 25% recurrence risk when both parents are heterozygous carriers; unaffected siblings have a 2/3 carrier probability after excluding disease.
  • Environmental, infectious, lifestyle, occupational, age, and sex risks: none are established as causes or susceptibility factors. Infections and diet may modify complications or edema burden but do not cause the Mendelian disorder.
  • Protective variants, modifier genes, or protective environmental exposures: none validated.
  • Gene–environment interaction: no HKLLS2-specific interaction has been demonstrated. Mechanical flow is biologically relevant to lymphatic-valve endothelial polarization, but evidence that exercise, diet, toxins, or infection alters penetrance of FAT4 disease is absent.

3. Phenotypes

Phenotype frequencies below must be interpreted cautiously: most are syndrome-wide observations, whereas the most detailed FAT4-specific evidence is essentially patient-level.

Core manifestations and suggested HPO annotations

  • Primary lymphedema—clinical sign/physical manifestation; HP:0001004. It may affect face/periorbital tissues, limbs, genitalia, or be generalized. FAT4-related edema can begin after birth or later in childhood, in contrast to the frequently congenital edema of CCBE1-related disease. Severity and distribution are variable and generally chronic. (ivanovski2018vanmaldergemsyndrome pages 1-2, ivanovski2018vanmaldergemsyndrome pages 7-8)
  • Lymphangiectasia, especially intestinal—clinical/pathologic sign; suggested HPO: intestinal lymphangiectasia. It may cause protein-losing enteropathy, abdominal distension, malabsorption, diarrhea, ascites, hypoalbuminemia, and hypogammaglobulinemia. (ivanovski2018vanmaldergemsyndrome pages 6-7, ivanovski2018vanmaldergemsyndrome pages 1-2)
  • Generalized/pitting edema—physical sign; suggested HPO: generalized edema/pitting edema. In one FAT4 patient it began at 8 months and included periorbital edema and abdominal distension. (ivanovski2018vanmaldergemsyndrome pages 6-7)
  • Characteristic face—hypertelorism (HP:0000316), epicanthus (HP:0000286), flat/wide nasal bridge, midface hypoplasia, synophrys, small/low-set ears, small mouth, and full lower lip. Conical/irregular teeth and gingival hypertrophy can occur. (ivanovski2018vanmaldergemsyndrome pages 6-7, ivanovski2018vanmaldergemsyndrome pages 7-8)
  • Developmental or intellectual effects—suggested HP:0001263 and HP:0001249. Syndrome-level descriptions emphasize mild intellectual disability, but expressivity is broad: the detailed p.Asp1766Gly patient had delayed complex language yet IQ 100–105, normal motor milestones, and normal brain MRI. (ivanovski2018vanmaldergemsyndrome pages 6-7, ivanovski2018vanmaldergemsyndrome pages 7-8)
  • Growth abnormalities: short stature and low weight were documented in the FAT4 patient (<3rd percentile at age seven); suggested HPO: short stature (HP:0004322) and underweight. (ivanovski2018vanmaldergemsyndrome pages 6-7)
  • Other reported findings: umbilical hernia, abdominal distension, recurrent respiratory/intestinal infections, fetal fingertip pads, and blurred/elevated optic discs. These are not established as frequent subtype-defining features. (ivanovski2018vanmaldergemsyndrome pages 6-7)

Laboratory abnormalities

In the p.Asp1766Gly patient, albumin was 2.2 g/dL, total protein 3.8 g/dL, IgM <0.25 g/L, IgG <1.98 g/L, IgE 410.7 IU/L, and eosinophils 13.8%. Endoscopy showed duodenal white spots and edematous/lacunar colonic mucosa, but biopsies did not demonstrate dilated lymphatics; thus, a negative focal biopsy does not exclude clinically important intestinal lymphatic disease. (ivanovski2018vanmaldergemsyndrome pages 6-7)

Quality of life

No FAT4-specific EQ-5D, SF-36, PROMIS, or disease-specific quality-of-life study was found. Expert primary-lymphedema guidance states that functional and psychological repercussions can be major, while chronic swelling, garment burden, mobility restriction, appearance, recurrent cellulitis, dietary restriction, and developmental needs plausibly drive impairment. This is guideline-level extrapolation, not a measured HKLLS2 statistic. (vignes2021primarylymphedemafrench pages 1-2)

4. Genetic and molecular information

FAT4 encodes a giant, calcium-dependent, atypical cadherin. The protein has 34 extracellular cadherin domains, compared with 27 in DCHS1, and forms a heterophilic trans-cellular receptor–ligand pair with DCHS1. (medina2023structureofthe pages 1-2)

Pathogenic classes reported across FAT4-associated recessive disease include damaging missense and truncating/splice-disrupting alleles, generally in homozygous or compound-heterozygous state. Variants are constitutional/germline, not somatic. Exact gnomAD allele frequencies and ClinVar classifications must be retrieved allele by allele; the p.Asp1766Gly report predates current gnomAD and only establishes absence from ExAC/1000 Genomes. (ivanovski2018vanmaldergemsyndrome pages 6-7)

No validated HKLLS2 modifier gene, epigenetic signature, recurrent chromosomal abnormality, anticipation mechanism, or germline-mosaicism series was identified. DCHS1 is a binding partner and an allelic-pathway gene, not an established modifier. Biallelic FAT4 variants can also produce Van Maldergem syndrome 2, demonstrating allelic phenotypic heterogeneity; no reliable genotype–phenotype correlation had been defined. (ivanovski2018vanmaldergemsyndrome pages 7-8, ivanovski2018vanmaldergemsyndrome pages 1-2)

5. Environmental, lifestyle, and infectious information

There is no evidence that toxins, radiation, pollution, smoking, alcohol, occupation, diet, or a pathogen initiates HKLLS2. Recurrent infection is a downstream complication of lymphatic dysfunction, skin-barrier disruption, protein loss, and hypogammaglobulinemia. Diet is therapeutic when intestinal lymphangiectasia is present; it is not primary prevention. Avoiding skin trauma and treating entry lesions may reduce cellulitis risk but cannot prevent the genetic disorder. (musumeci2006cutaneousmanifestationsand pages 3-4, vignes2021primarylymphedemafrench pages 1-2)

6. Mechanism and pathophysiology

Causal chain

  1. Upstream genetic lesion: biallelic damaging FAT4 variants reduce normal FAT4-mediated intercellular signaling.
  2. Molecular defect: FAT4 cannot correctly engage DCHS1 across adjacent cells or transmit normal planar-cell-polarity information.
  3. Cellular defect: lymphatic valve endothelial cells fail to polarize and reorient perpendicular to the vessel axis; collective migration, actin organization, and junctional rearrangement are impaired.
  4. Developmental defect: valve initiation can occur and the broad lymphatic network can remain present, but valve leaflets fail to mature normally.
  5. Physiologic result: incompetent lymph transport produces interstitial fluid retention and lymphedema; intestinal lymphatic dysfunction produces lymph/protein loss, hypoalbuminemia, immune-protein loss, edema, and malabsorption. (pujol2017dachsous1–fat4signalingcontrols pages 2-4, pujol2017dachsous1–fat4signalingcontrols pages 1-2)

In Fat4- and Dchs1-deficient mice, approximately 60% of lymphatic valves were abnormal at P0. Only 23% of FAT4-deficient and 43% of DCHS1-deficient valve endothelial cells achieved the specified proper orientation, versus 83% in controls. Overall lymphatic architecture and initial Prox1-high clusters were comparatively preserved, localizing the major defect to valve morphogenesis. Reduced FnEIIIA and integrin-α9 staining suggests impaired integrin-supported migration downstream. (pujol2017dachsous1–fat4signalingcontrols pages 1-2)

Although FAT4/DCHS1 can intersect Hippo signaling in other tissues, the lymphatic-valve study did not find significant junctional recruitment of TAZ or Merlin consistent with a simple canonical-Hippo mechanism. The best-supported lymphatic mechanism is therefore planar cell polarity and endothelial polarization, with Hippo involvement context-dependent rather than proven as the direct cause of HKLLS2 lymphatic disease. (pujol2017dachsous1–fat4signalingcontrols pages 2-4, pujol2017dachsous1–fat4signalingcontrols pages 14-15)

Recent mechanistic development

Medina et al., accepted 1 February 2023 and published in Nature Communications 14:891, solved human FAT4–DCHS1 co-crystal structures. Their abstract reports that the binding interface extends across EC1–EC4 and contains an unusually extensive salt-bridge network; extracellular phosphorylation may modulate binding. PDB entries include 8EGW and 8EGX. This provides structural—not yet therapeutic—resolution of the disease-relevant receptor–ligand interface. DOI: https://doi.org/10.1038/s41467-023-36435-x. (medina2023structureofthe pages 9-10, medina2023structureofthe pages 1-2)

Suggested ontology annotations

  • GO biological processes: planar cell polarity; cell–cell adhesion; endothelial cell migration; actin cytoskeleton organization; lymph vessel development; lymphatic valve morphogenesis; regulation of tissue fluid homeostasis.
  • GO cellular components: plasma membrane, cell–cell junction, extracellular region/cadherin complex; mitochondrial association has been described for cleaved Fat-family intracellular domains but is not established as the HKLLS2 lymphatic mechanism.
  • Cell Ontology: lymphatic endothelial cell; valve endothelial cell (use the closest current CL term and retain “Prox1-high lymphatic valve endothelial cell” as a textual qualifier).
  • Biochemical abnormality: receptor/adhesion-signaling dysfunction rather than enzyme deficiency or ion-channel disease.

No HKLLS2-specific patient transcriptome, proteome, metabolome, lipidome, single-cell atlas, spatial transcriptome, CRISPR screen, or integrated multi-omics study was identified. Such fields should be recorded as not available, rather than inferred from general lymphedema datasets.

7. Anatomical structures affected

Primary sites are dermal/subcutaneous lymphatic vessels and collecting-vessel valves, with clinically visible involvement of extremities, face/periorbital tissues, genitalia, and abdominal wall. The gastrointestinal tract—particularly intestinal lacteals/lymphatics—is a major visceral site. Secondary involvement can include serous cavities through ascites/effusions, skin through chronic edema and fibrosis, and immune function through intestinal protein/immunoglobulin loss. (ivanovski2018vanmaldergemsyndrome pages 1-2, ivanovski2018vanmaldergemsyndrome pages 6-7)

Suggested annotations include UBERON: lymphatic vessel, lymphatic valve, skin/subcutaneous tissue, small intestine/duodenum, colon, face, upper limb, lower limb, external genitalia, and peritoneal cavity. Lymphedema may be bilateral/generalized or asymmetric/unilateral; one syndrome-level rehabilitation case had unilateral arm disease, but this was not genetically confirmed as FAT4-related. (lee2018hennekamsyndromea pages 3-5)

8. Temporal development

HKLLS2 is a congenital developmental disorder, even when swelling is not evident neonatally. FAT4-related lymphedema may emerge in infancy or later childhood; in the best-documented patient it began at 8 months, while the comparative series states that FAT4 cases can begin later than CCBE1 cases, which are often edematous at birth. (ivanovski2018vanmaldergemsyndrome pages 6-7, ivanovski2018vanmaldergemsyndrome pages 7-8)

The expected course is chronic and lifelong, with variable progression and fluctuation according to dependent fluid load, infection, protein loss, compression adherence, and tissue remodeling. Formal stages or subtype-specific progression rates do not exist. Spontaneous cure has not been documented. Early recognition is important before recurrent infection, fibrosis, adipose deposition, severe protein loss, or irreversible functional impairment develops. General primary-lymphedema guidance notes that lymph accumulation drives skin thickening and adipose deposition. (vignes2021primarylymphedemafrench pages 1-2)

9. Inheritance and population

Inheritance is autosomal recessive. Penetrance has not been quantified, expressivity is clearly variable, and no anticipation is expected. Consanguinity is represented in reported families but is not required. No validated founder allele, carrier frequency, ethnic enrichment, geographic concentration, sex ratio, incidence, or prevalence estimate exists for HKLLS2. (ivanovski2018vanmaldergemsyndrome pages 6-7, ivanovski2018vanmaldergemsyndrome pages 7-8)

The statement “40 patients” refers to all clinically reported Hennekam syndrome by 2018, not HKLLS2 prevalence. Of those, 13 had CCBE1 variants, two had ADAMTS3 variants, and many remained molecularly unresolved; therefore, these counts cannot support a population rate or FAT4 penetrance estimate. (ivanovski2018vanmaldergemsyndrome pages 7-8, ivanovski2018vanmaldergemsyndrome pages 1-2)

10. Diagnostics

Recommended workflow

  1. Clinical assessment: map edema distribution and onset; inspect skin and genitalia; document facial/dental, developmental, growth, GI, respiratory, neurologic, ophthalmic, hearing, skeletal, and family-history findings. Stemmer sign supports lymphedema but is not specific to HKLLS2. (vignes2021primarylymphedemafrench pages 1-2)
  2. Exclude acquired edema: renal, hepatic, cardiac, venous, medication-related, infectious/filariasis, malnutrition, lipedema, and secondary lymphatic injury.
  3. Laboratory evaluation: CBC; albumin/total protein; immunoglobulins; electrolytes, renal and hepatic indices; stool α1-antitrypsin clearance when protein-losing enteropathy is suspected; fat-soluble vitamins and micronutrients according to GI severity.
  4. Imaging: limb lymphoscintigraphy can confirm impaired lymph transport. Ultrasound, MRI/MR lymphangiography, CT, echocardiography, or targeted organ imaging is selected by phenotype. (lee2018hennekamsyndromea pages 3-5, vignes2021primarylymphedemafrench pages 1-2)
  5. GI evaluation: endoscopy/biopsy for suspected intestinal lymphangiectasia, recognizing patchiness and possible false-negative biopsy. (ivanovski2018vanmaldergemsyndrome pages 6-7)
  6. Molecular confirmation: a comprehensive primary-lymphedema/lymphatic-anomaly panel including FAT4, CCBE1, ADAMTS3, DCHS1, FLT4, FOXC2, GATA2, PIEZO1, EPHB4, CELSR1 and other validated genes is efficient. The published FAT4 patient was diagnosed on a 36-gene lymphedema panel. If negative, trio WES or WGS with copy-number and splice-aware analysis is appropriate. (ivanovski2018vanmaldergemsyndrome pages 6-7)

Single-gene FAT4 testing is reasonable when phenotype and segregation are highly characteristic. WES/WGS is particularly useful for atypical disease, phenotypic overlap with Van Maldergem syndrome, or a negative panel. CMA/karyotype may evaluate an alternative syndromic diagnosis but are not primary tests for a single-nucleotide/small-indel FAT4 disorder; karyotype and array-CGH were normal in reported cases. FISH, mitochondrial DNA, repeat-expansion, liquid-biopsy, proteomic, metabolomic, and epigenomic testing have no established diagnostic role. (ivanovski2018vanmaldergemsyndrome pages 6-7)

Differential diagnosis

Major alternatives are CCBE1-related HKLLS1; ADAMTS3-related HKLLS3; Van Maldergem syndrome 2; Milroy disease/FLT4; lymphedema-distichiasis/FOXC2; PIEZO1-related generalized lymphatic dysplasia; GATA2 deficiency/Emberger syndrome; Noonan-spectrum disorders; primary intestinal lymphangiectasia; and CHAPLE/CD55 deficiency. VMS overlaps in face and neurodevelopment but more typically has neonatal hypotonia, feeding/breathing problems, tracheal anomalies, hearing loss, osteopenia, camptodactyly, and less prominent lymphatic disease. (ivanovski2018vanmaldergemsyndrome pages 1-2, ivanovski2018vanmaldergemsyndrome pages 7-8)

There are no universally accepted HKLLS2-specific diagnostic criteria and no population or newborn screening program. Cascade testing is appropriate after a familial variant is identified.

11. Outcome and prognosis

No 5- or 10-year survival, life expectancy, disease-specific mortality, or validated prognostic-biomarker data exist. Prognosis is probably driven by extent of lymphatic disease, protein-losing enteropathy, serous effusions, recurrent infection, nutritional deficiency, and developmental/airway or other organ involvement. This is clinical inference, not a validated model.

Morbidity includes chronic swelling, reduced mobility or dexterity, skin thickening/fibrosis, genital involvement, cellulitis/erysipelas, abdominal symptoms, malnutrition, hypoalbuminemia, immune-protein loss, and psychosocial burden. Cellulitis is the principal acute complication in primary lymphedema generally. Edema can improve substantially but usually requires lifelong control; structural lymphatic dysplasia is not expected to recover completely. (musumeci2006cutaneousmanifestationsand pages 3-4, vignes2021primarylymphedemafrench pages 1-2)

12. Treatment and current applications

There is no approved FAT4-directed or curative therapy. Care is multidisciplinary and phenotype-directed.

Lymphedema care

Complete decongestive therapy combines low-stretch multilayer bandaging, appropriately fitted compression garments, manual lymph drainage where indicated, exercise with compression, skin care, weight/mobility optimization, limb elevation, and patient/family education. The French national protocol describes reduction with low-stretch bandages followed by long-term stabilization through exercise and compression. (vignes2021primarylymphedemafrench pages 1-2)

In one non-genotyped Hennekam case, seven sessions combining drainage, prolonged compression, exercise, and low-level laser therapy reduced upper-arm circumference from 22 to 19 cm and forearm circumference from 22.5 to 21 cm. This uncontrolled observation supports feasibility, not laser efficacy or FAT4-specific response. (lee2018hennekamsyndromea pages 3-5)

Suggested NCIT intervention concepts include Compression Therapy, Physical Therapy, Exercise Therapy, Manual Lymphatic Drainage, Nutritional Support, and Genetic Counseling; exact current NCIT codes should be resolved against the live thesaurus.

Intestinal lymphangiectasia/protein loss

Use a high-protein, low-long-chain-fat diet with medium-chain triglycerides, individualized by a metabolic dietitian. Monitor growth, albumin, immunoglobulins, electrolytes, vitamins, and trace elements. Albumin infusion can be used for severe symptomatic hypoalbuminemia; the FAT4 patient received albumin after edema began. It replaces loss temporarily and does not correct the lymphatic defect. (ivanovski2018vanmaldergemsyndrome pages 6-7, musumeci2006cutaneousmanifestationsand pages 3-4)

Infection and surgery

Meticulous hygiene, emollients, treatment of fissures/tinea, and prompt systemic antibiotics for cellulitis are central. Recurrent cellulitis may justify prophylactic antibiotics under specialist protocols. Debulking, lymphaticovenous anastomosis, vascularized lymph-node transfer, or other reconstructive procedures may be considered in selected refractory anatomy, but historical Hennekam surgery has had frequent recurrence/complications and no FAT4-specific outcome series exists. Intermittent pneumatic compression deserves caution in children or genital disease. (musumeci2006cutaneousmanifestationsand pages 3-4)

No HKLLS2 pharmacogenomic guidance, gene therapy, cell therapy, RNA therapy, immunotherapy, approved targeted drug, or relevant disease-specific interventional trial was identified. Patent searching likewise produced no credible FAT4-Hennekam therapeutic implementation.

13. Prevention

The genotype itself cannot be prevented by lifestyle change. Primary reproductive prevention/options include carrier testing of relatives, genetic counseling, prenatal diagnosis, and preimplantation genetic testing when familial pathogenic variants are known. Secondary prevention consists of early diagnosis in siblings and early assessment for edema, GI protein loss, growth failure, and developmental needs. Tertiary prevention includes compression/exercise, skin care, cellulitis education, nutritional surveillance, immunization according to routine schedules, and prompt treatment of infection. No disease-specific vaccine, chemoprophylaxis, environmental intervention, or public-health screening program exists. (musumeci2006cutaneousmanifestationsand pages 3-4, vignes2021primarylymphedemafrench pages 1-2)

14. Other species and natural disease

No naturally occurring veterinary syndrome clearly homologous to human FAT4-related HKLLS2 was identified. Thus, breed enrichment, VBO annotation, veterinary prevalence, transmission, and zoonotic potential are not applicable/unknown. FAT4 orthologs and the FAT–Dachsous polarity system are evolutionarily conserved across metazoans, but experimental ortholog phenotypes should not be described as spontaneous Hennekam disease. (medina2023structureofthe pages 1-2)

15. Model organisms

The principal model is the Fat4-null mouse (Mus musculus, NCBI Taxonomy 10090), with Dchs1-null mice serving as pathway-comparison models. Both are genetic knockout models. They reproduce defective lymphatic-valve endothelial orientation and leaflet morphogenesis, directly supporting the lymphedema mechanism; they also show broader developmental abnormalities and die shortly after birth, limiting modeling of chronic human survival and treatment response. (medina2023structureofthe pages 1-2, pujol2017dachsous1–fat4signalingcontrols pages 1-2)

Relevant in-vitro systems include cultured lymphatic endothelial cells and HEK293 co-expression assays. FAT4 and DCHS1 are recruited to cell–cell contacts; DCHS1 localizes to protrusions and junctions. These systems are useful for adhesion, polarization, phosphorylation, and variant-binding assays but do not reproduce whole-organ lymph flow, intestinal protein loss, or neurodevelopment. (pujol2017dachsous1–fat4signalingcontrols pages 2-4, medina2023structureofthe pages 9-10)

The 2023 structural work adds purified-protein crystallography and AlphaFold-assisted modeling, with structures PDB 8EGW/8EGX. No HKLLS2-specific zebrafish, organoid, patient-iPSC, rat, Drosophila disease-model, or humanized mouse treatment platform was identified in the retrieved literature. (medina2023structureofthe pages 9-10)

Key exact quotations from primary/authoritative sources

  • Ivanovski et al., published May 2018: “Biallelic variants in FAT4 are associated with the two disorders, Van Maldergem syndrome (VMS) … and Hennekam syndrome (HS) ….” DOI: https://doi.org/10.1002/ajmg.a.38652. (ivanovski2018vanmaldergemsyndrome pages 1-2)
  • Pujol et al., published September 2017: “The overall architecture of lymphatic vasculature is unaltered, yet both genes are specifically required for lymphatic valve morphogenesis.” DOI: https://doi.org/10.1161/ATVBAHA.117.309818. (pujol2017dachsous1–fat4signalingcontrols pages 1-2)
  • The same study concluded: “This study highlights that valve defects may contribute to lymphedema in Hennekam syndrome caused by Fat4 mutations.” (pujol2017dachsous1–fat4signalingcontrols pages 1-2)
  • Medina et al., accepted 1 February 2023: “The binding domains of Fat4 and Dchs1 form an extended interface along extracellular cadherin (EC) domains 1–4 of each protein.” DOI: https://doi.org/10.1038/s41467-023-36435-x. (medina2023structureofthe pages 1-2)
  • French National Diagnosis and Care Protocol, published January 2021: “Treatment aims to prevent those complications, reduce the volume with low-stretch bandages, then stabilize it over the long term by exercises and wearing a compression garment.” DOI: https://doi.org/10.1186/s13023-020-01652-w. (vignes2021primarylymphedemafrench pages 1-2)

Evidence gaps and expert interpretation

The principal limitation is not conflicting evidence but scarcity. No large FAT4-specific natural-history cohort, registry-derived epidemiology, prospective treatment trial, standardized outcome set, patient-reported outcome study, or 2023–2024 subtype-specific clinical series was found. The most important recent advance is the 2023 structural definition of the FAT4–DCHS1 interface; 2024 literature mainly updates general lymphatic-development biology rather than HKLLS2 clinical care. Accordingly, exact phenotype percentages, sex ratios, prevalence, penetrance, life expectancy, response rates, allele frequencies, and prognostic biomarkers should be stored as unknown, while patient-level observations should retain their provenance and denominator. The most defensible current model is biallelic FAT4 dysfunction → disturbed DCHS1–FAT4 planar polarity → failed lymphatic-valve endothelial reorientation and leaflet maturation → impaired lymph transport, lymphedema, and visceral lymphangiectasia. (pujol2017dachsous1–fat4signalingcontrols pages 1-2, medina2023structureofthe pages 9-10, ivanovski2018vanmaldergemsyndrome pages 7-8)

References

  1. (ivanovski2018vanmaldergemsyndrome pages 7-8): Ivan Ivanovski, Susan Akbaroghli, Marzia Pollazzon, Chiara Gelmini, Stefano Giuseppe Caraffi, Mahboubeh Mansouri, Zahra Chavoshzadeh, Simonetta Rosato, Valeria Polizzi, Giancarlo Gargano, Marielle Alders, Livia Garavelli, and Raoul C. Hennekam. Van maldergem syndrome and hennekam syndrome: further delineation of allelic phenotypes. American Journal of Medical Genetics Part A, 176:1166-1174, May 2018. URL: https://doi.org/10.1002/ajmg.a.38652, doi:10.1002/ajmg.a.38652. This article has 33 citations.

  2. (ivanovski2018vanmaldergemsyndrome pages 1-2): Ivan Ivanovski, Susan Akbaroghli, Marzia Pollazzon, Chiara Gelmini, Stefano Giuseppe Caraffi, Mahboubeh Mansouri, Zahra Chavoshzadeh, Simonetta Rosato, Valeria Polizzi, Giancarlo Gargano, Marielle Alders, Livia Garavelli, and Raoul C. Hennekam. Van maldergem syndrome and hennekam syndrome: further delineation of allelic phenotypes. American Journal of Medical Genetics Part A, 176:1166-1174, May 2018. URL: https://doi.org/10.1002/ajmg.a.38652, doi:10.1002/ajmg.a.38652. This article has 33 citations.

  3. (OpenTargets Search: Hennekam lymphangiectasia-lymphedema syndrome 2-FAT4): Open Targets Query (Hennekam lymphangiectasia-lymphedema syndrome 2-FAT4, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  4. (medina2023structureofthe pages 1-2): Elliot Medina, Yathreb Easa, Daniel K. Lester, Eric K. Lau, David Sprinzak, and Vincent C. Luca. Structure of the planar cell polarity cadherins fat4 and dachsous1. Nature Communications, Feb 2023. URL: https://doi.org/10.1038/s41467-023-36435-x, doi:10.1038/s41467-023-36435-x. This article has 23 citations and is from a highest quality peer-reviewed journal.

  5. (pujol2017dachsous1–fat4signalingcontrols pages 1-2): Francoise Pujol, Tina Hodgson, Ines Martinez-Corral, Anne-Catherine Prats, Danelle Devenport, Masatoshi Takeichi, Elisabeth Genot, Taija Mäkinen, Philippa Francis-West, Barbara Garmy-Susini, and Florence Tatin. Dachsous1–fat4 signaling controls endothelial cell polarization during lymphatic valve morphogenesis—brief report. Arteriosclerosis, Thrombosis, and Vascular Biology, 37:1732–1735, Sep 2017. URL: https://doi.org/10.1161/atvbaha.117.309818, doi:10.1161/atvbaha.117.309818. This article has 49 citations and is from a domain leading peer-reviewed journal.

  6. (pujol2017dachsous1–fat4signalingcontrols pages 2-4): Francoise Pujol, Tina Hodgson, Ines Martinez-Corral, Anne-Catherine Prats, Danelle Devenport, Masatoshi Takeichi, Elisabeth Genot, Taija Mäkinen, Philippa Francis-West, Barbara Garmy-Susini, and Florence Tatin. Dachsous1–fat4 signaling controls endothelial cell polarization during lymphatic valve morphogenesis—brief report. Arteriosclerosis, Thrombosis, and Vascular Biology, 37:1732–1735, Sep 2017. URL: https://doi.org/10.1161/atvbaha.117.309818, doi:10.1161/atvbaha.117.309818. This article has 49 citations and is from a domain leading peer-reviewed journal.

  7. (ivanovski2018vanmaldergemsyndrome pages 6-7): Ivan Ivanovski, Susan Akbaroghli, Marzia Pollazzon, Chiara Gelmini, Stefano Giuseppe Caraffi, Mahboubeh Mansouri, Zahra Chavoshzadeh, Simonetta Rosato, Valeria Polizzi, Giancarlo Gargano, Marielle Alders, Livia Garavelli, and Raoul C. Hennekam. Van maldergem syndrome and hennekam syndrome: further delineation of allelic phenotypes. American Journal of Medical Genetics Part A, 176:1166-1174, May 2018. URL: https://doi.org/10.1002/ajmg.a.38652, doi:10.1002/ajmg.a.38652. This article has 33 citations.

  8. (pujol2017dachsous1–fat4signalingcontrols pages 4-8): Francoise Pujol, Tina Hodgson, Ines Martinez-Corral, Anne-Catherine Prats, Danelle Devenport, Masatoshi Takeichi, Elisabeth Genot, Taija Mäkinen, Philippa Francis-West, Barbara Garmy-Susini, and Florence Tatin. Dachsous1–fat4 signaling controls endothelial cell polarization during lymphatic valve morphogenesis—brief report. Arteriosclerosis, Thrombosis, and Vascular Biology, 37:1732–1735, Sep 2017. URL: https://doi.org/10.1161/atvbaha.117.309818, doi:10.1161/atvbaha.117.309818. This article has 49 citations and is from a domain leading peer-reviewed journal.

  9. (medina2023structureofthe pages 9-10): Elliot Medina, Yathreb Easa, Daniel K. Lester, Eric K. Lau, David Sprinzak, and Vincent C. Luca. Structure of the planar cell polarity cadherins fat4 and dachsous1. Nature Communications, Feb 2023. URL: https://doi.org/10.1038/s41467-023-36435-x, doi:10.1038/s41467-023-36435-x. This article has 23 citations and is from a highest quality peer-reviewed journal.

  10. (vignes2021primarylymphedemafrench pages 1-2): Stéphane Vignes, Juliette Albuisson, Laurence Champion, Joël Constans, Valérie Tauveron, Julie Malloizel, Isabelle Quéré, Laura Simon, Maria Arrault, Patrick Trévidic, Philippe Azria, and Annabel Maruani. Primary lymphedema french national diagnosis and care protocol (pnds; protocole national de diagnostic et de soins). Orphanet Journal of Rare Diseases, Jan 2021. URL: https://doi.org/10.1186/s13023-020-01652-w, doi:10.1186/s13023-020-01652-w. This article has 45 citations and is from a peer-reviewed journal.

  11. (lee2018hennekamsyndromea pages 3-5): Yeong Guk Lee, Seung Chan Kim, Si-Bog Park, and Mi Jung Kim. Hennekam syndrome: a case report. Annals of Rehabilitation Medicine, 42:184-188, Feb 2018. URL: https://doi.org/10.5535/arm.2018.42.1.184, doi:10.5535/arm.2018.42.1.184. This article has 11 citations.

  12. (musumeci2006cutaneousmanifestationsand pages 3-4): Maria Letizia Musumeci, Maria Rita Nasca, Rocco De Pasquale, Robert A. Schwartz, and Giuseppe Micali. Cutaneous manifestations and massive genital involvement in hennekam syndrome. Pediatric Dermatology, 23:239-242, May 2006. URL: https://doi.org/10.1111/j.1525-1470.2006.00225.x, doi:10.1111/j.1525-1470.2006.00225.x. This article has 23 citations and is from a peer-reviewed journal.

  13. (pujol2017dachsous1–fat4signalingcontrols pages 14-15): Francoise Pujol, Tina Hodgson, Ines Martinez-Corral, Anne-Catherine Prats, Danelle Devenport, Masatoshi Takeichi, Elisabeth Genot, Taija Mäkinen, Philippa Francis-West, Barbara Garmy-Susini, and Florence Tatin. Dachsous1–fat4 signaling controls endothelial cell polarization during lymphatic valve morphogenesis—brief report. Arteriosclerosis, Thrombosis, and Vascular Biology, 37:1732–1735, Sep 2017. URL: https://doi.org/10.1161/atvbaha.117.309818, doi:10.1161/atvbaha.117.309818. This article has 49 citations and is from a domain leading peer-reviewed journal.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 7
Resolved 7
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 7
On topic 5
Off topic 0

All extracted references resolved successfully.

OpenScientist ▸
Hennekam Lymphangiectasia–Lymphedema Syndrome 2 (HKLLS2): Comprehensive Disease Characteristics Report
openscientist-autonomous 19 citations 2026-09-02T05:44:03.549292

Hennekam Lymphangiectasia–Lymphedema Syndrome 2 (HKLLS2): Comprehensive Disease Characteristics Report

Disease: Hennekam lymphangiectasia-lymphedema syndrome 2 (HKLLS2) OMIM: #616006 · MONDO: MONDO:0014217 · Orphanet: ORPHA:2136 (Hennekam syndrome) · ICD-10: Q82.0 (hereditary lymphedema) Causal gene: FAT4 (FAT atypical cadherin 4; HGNC:23109; 4q28.1) · Inheritance: Autosomal recessive Category: Mendelian

Summary

Hennekam lymphangiectasia-lymphedema syndrome 2 (HKLLS2) is an ultra-rare, autosomal recessive generalized lymphatic dysplasia caused by biallelic loss-of-function variants in FAT4, an atypical Fat/Dachsous-family cadherin located at 4q28.1. It is the second genetically defined form of Hennekam syndrome — HKLLS1 is caused by CCBE1 and HKLLS3 by ADAMTS3 — and is allelic to Van Maldergem syndrome (VMS), which arises from FAT4 or DCHS1 mutations and shares a facial gestalt and intellectual disability but generally lacks the lymphedema that defines Hennekam syndrome. The disease was molecularly delineated by Alders and colleagues in 2014 through homozygosity mapping and whole-exome sequencing of the original Hennekam family, in whom no CCBE1 mutation had been found (PMID: 24913602).

Mechanistically, FAT4 acts cell-autonomously in lymphatic endothelial cells (LECs) to establish planar cell polarity (PCP) in response to fluid flow, working with its binding partner Dachsous1 (DCHS1) to drive lymphatic valve and vessel morphogenesis. Loss of FAT4 disrupts LEC polarization, causing defective lymphatic valves and dysfunctional lymphatic drainage; this converges on the same VEGF-C/VEGFR3 prolymphangiogenic axis in which CCBE1 and ADAMTS3 operate (by proteolytically activating pro-VEGF-C). FAT4/DCHS1 signaling additionally regulates Hippo/YAP-dependent cortical neurogenesis, which explains the neurodevelopmental features. The downstream clinical consequences form a characteristic tetrad: congenital/generalized lymphedema, intestinal lymphangiectasia with protein-losing enteropathy (PLE), facial dysmorphism, and variable (mild-to-moderate) intellectual disability, with additional multisystem involvement (chylous effusions, pericardial effusion, hearing loss, hypogammaglobulinemia).

There is no curative therapy. Management is supportive and multidisciplinary: complete decongestive therapy for lymphedema, high-protein/low-fat/medium-chain-triglyceride nutrition and albumin/immunoglobulin support for intestinal lymphangiectasia and PLE, drainage/management of effusions, and symptomatic care of dysmorphic, cognitive, and sensory features. Diagnosis is established by molecular genetic testing (exome/genome sequencing or a primary-lymphedema gene panel including CCBE1, FAT4, ADAMTS3) within the standardized primary lymphatic dysplasia diagnostic pathway, supported by imaging (lymphoscintigraphy, MR lymphangiography), intestinal biopsy showing lymphangiectasia, and laboratory evidence of hypoalbuminemia and hypogammaglobulinemia. Prevention relies on genetic counseling with the option of prenatal or preimplantation genetic testing in at-risk families.

Evidence base: this is an ultra-rare disorder (~50 Hennekam-syndrome cases reported worldwide; the FAT4 subtype a minority). Nearly all information derives from individual patient case reports/small cohorts (human clinical), model-organism studies (mouse, Drosophila), and in vitro biochemistry — not from large aggregated registries or EHR datasets. Where data are absent, this is stated explicitly.

Key Findings

Finding 1 — HKLLS2 is caused by biallelic loss-of-function FAT4 variants (autosomal recessive; OMIM #616006)

The genetic basis of HKLLS2 was established by Alders et al. (2014). Using homozygosity mapping combined with whole-exome sequencing in the original Hennekam family — in whom CCBE1 mutations had been excluded — they identified a homozygous FAT4 mutation, then confirmed the gene by targeted analysis of a CCBE1-negative cohort:

"We used homozygosity mapping and whole-exome sequencing in the original HS family with multiple affected individuals in whom no CCBE1 mutation had been detected, and identified a homozygous mutation in the FAT4 gene. Subsequent targeted mutation analysis of FAT4 in a cohort of 24 CCBE1 mutation-negative Hennekam syndrome patients identified homozygous or compound heterozygous mutations in four additional families." — PMID: 24913602

The autosomal recessive inheritance and the OMIM identifier #616006 for the FAT4-associated form are corroborated in the ADAMTS3 delineation paper:

"It is an autosomal recessive condition caused by biallelic mutations in CCBE1 ... (HKLLS1; OMIM 235510) or FAT4 (HKLLS2; OMIM 616006)." — PMID: 30450763

Reported FAT4 variants are biallelic — homozygous in consanguineous families or compound heterozygous — and predominantly loss-of-function: missense, nonsense, frameshift, and splice-site changes. A 2026 report described a novel biallelic intron-14 splice variant (c.12479+3A>G) causing HKLLS2, with aberrant splicing confirmed by RT-PCR of patient fibroblasts (PMID: 41992670). FAT4 is allelic to Van Maldergem syndrome, so the same gene produces distinct but overlapping phenotypes depending on variant and modifier context.

Finding 2 — FAT4 controls LEC polarity and lymphatic valve morphogenesis, converging on the VEGF-C/VEGFR3 pathway shared by all Hennekam genes

FAT4 is the molecular linchpin of HKLLS2 pathophysiology. Betterman et al. (2020) demonstrated that FAT4 functions within LECs to sense flow and establish polarity, and that it is a transcriptional target of the lymphatic master regulator GATA2:

"we demonstrate that FAT4 functions in a lymphatic endothelial cell-autonomous manner to control cell polarity in response to flow and is required for lymphatic vessel morphogenesis throughout development" — PMID: 32182215

Pujol et al. (2017) showed that the Dachsous1–Fat4 PCP module directs endothelial cell polarization specifically during lymphatic valve morphogenesis, and directly linked valve defects to the lymphedema seen in FAT4-Hennekam syndrome:

"Our data demonstrate that Fat4 and Dachsous1 are critical regulators of valve morphogenesis. This study highlights that valve defects may contribute to lymphedema in Hennekam syndrome caused by Fat4 mutations." — PMID: 28705793

Crucially, all three principal Hennekam genes act in a shared prolymphangiogenic pathway. CCBE1 (a matrix protein) and ADAMTS3 (a protease) proteolytically cleave and activate pro-VEGF-C, enabling VEGFR3 signaling, while FAT4 governs the endothelial polarity required to build functional vessels and valves:

"encoding a matrix protein and protease, respectively, that regulate activity of the key prolymphangiogenic VEGF-C/VEGFR3 signaling axis by facilitating the proteolytic cleavage and activation of VEGF-C. The fact that FAT4, CCBE1, and ADAMTS3 mutations underlie Hennekam syndrome suggested that all 3 genes might function in a common pathway" — PMID: 32182215

The VEGF-C activation mechanism is further supported by biochemical work showing that an ADAMTS3–CCBE1 complex is required to convert VEGF-C (but not VEGF-D) into an active VEGFR3 ligand (PMID: 27159393) and that the two domains of CCBE1 promote VEGFR3 signaling by distinct mechanisms (PMID: 28687807). PROX1 (master LEC identity factor) and VEGFR-3 form the developmental backbone of this system (PMID: 29842991).

Finding 3 — Core clinical phenotype: congenital lymphedema, intestinal lymphangiectasia/PLE, facial dysmorphism, and variable intellectual disability

Ivanovski, Alders, and Hennekam (2018) reviewed all reported FAT4 patients (VMS n=11, HS n=40), delineating the shared and distinguishing features of the two allelic conditions:

"Both conditions are characterized by a typical facial gestalt and mild to moderate intellectual disability, but differ in the occurrence of neonatal hypotonia and feeding problems, hearing loss, tracheal anomalies, and osteopenia in VMS, and lymphedema in HS." — PMID: 29681106

Individual case reports document the full clinical spectrum: generalized/peripheral lymphedema, facial anomalies (hypertelorism, flat nasal bridge, flat facial profile), camptodactyly, hypotonia, and duodenal lymphangiectasia with hypoalbuminemia and hypogammaglobulinemia (PMID: 25616299, PMID: 41992670). The intestinal lymphangiectasia (a form of Waldmann disease) drives protein-losing enteropathy as a downstream consequence:

"Primary intestinal lymphangiectasia (WD) is a consequence of HS, which ultimately results in PLE and worsening interstitial lymph buildup." — PMID: 38028107

Finding 4 — Model organisms recapitulate PCP, kidney, neural, and lymphatic phenotypes

Fat4-null mice and Drosophila fat mutants provide strong cross-species mechanistic support. In mouse (NCBI Taxon 10090; gene Fat4), Saburi et al. (2008) established the PCP role:

"Loss of Fat4 disrupts oriented cell divisions and tubule elongation during kidney development, leading to cystic kidney disease. Fat4 genetically interacts with the PCP genes Vangl2 and Fjx1 in cyst formation." — PMID: 18604206

Cappello et al. (2013) recapitulated the neurodevelopmental component and linked FAT4/DCHS1 to Hippo/YAP signaling:

"Reducing the expression of Dchs1 or Fat4 within mouse embryonic neuroepithelium increased progenitor cell numbers and reduced their differentiation into neurons, resulting in the heterotopic accumulation of cells below the neuronal layers in the neocortex, reminiscent of the human phenotype. These effects were countered by concurrent knockdown of Yap" — PMID: 24056717

The lymphatic-specific phenotype is captured by Fat4-deficient mice with defective valve morphogenesis and endothelial polarity (PMID: 28705793, PMID: 32182215). In Drosophila (Taxon 7227; ortholog fat), neuron-specific fat knockdown provides a model relevant to the intellectual-disability/neuronal features:

"Neuron-specific knockdown of fat shortened the life span and induced the defect in locomotive abilities of adult flies... Both VMS and HS show mental retardation and neuronal defects. We therefore consider that these two rare human diseases could possibly be caused by the defect in FAT4 function in neuronal cells." — PMID: 28488382

Finding 5 — Management is supportive; no curative therapy exists

There is no disease-modifying or curative treatment for HKLLS2. Lee et al. (2018) summarize the rehabilitative approach:

"There is no curative therapy at this time, but rehabilitative treatments including complete decongestive therapy for edema control appeared to be beneficial." — PMID: 29560340

Management is therefore symptomatic and multidisciplinary: complete decongestive therapy (manual lymphatic drainage, compression, exercise, skin care) for lymphedema; nutritional management of intestinal lymphangiectasia/PLE with a high-protein, low-fat, medium-chain-triglyceride diet plus correction of hypoalbuminemia and hypogammaglobulinemia; drainage/management of chylous and pericardial effusions (PMID: 26686525); and symptomatic care for facial dysmorphism, intellectual disability, hearing loss, and cardiac anomalies.

Finding 6 — Gene/protein identifiers, variant spectrum, and epidemiology

FAT4 (FAT atypical cadherin 4) identifiers: HGNC:23109, NCBI Gene 79633, Ensembl ENSG00000196159, UniProt Q6V0I7, cytoband 4q28.1. The gene encodes a very large (~4,981-aa) single-pass atypical cadherin — the vertebrate ortholog of Drosophila Fat — with 34 extracellular cadherin repeats, EGF-like domains, and laminin-G domains:

"The FAT4 gene encodes a large protein with extracellular cadherin repeats, EGF-like domains and Laminin G-like domains." — PMID: 28488382

Disease identifiers: OMIM #616006; MONDO:0014217; Orphanet ORPHA:2136 (Hennekam syndrome); ICD-10 Q82.0. Within Hennekam syndrome overall, CCBE1 accounts for approximately 25% of cases, with FAT4 and ADAMTS3 explaining additional subsets:

"It can be caused by mutations in CCBE1 which are found in approximately 25 % of cases." — PMID: 24913602

Hennekam syndrome is ultra-rare (Orphanet prevalence <1/1,000,000). As of 2023, roughly 50 cases had been reported worldwide:

"As far as we know, this is the 51st case of HS worldwide and the first one in an African American." — PMID: 38028107

Finding 7 — Diagnosis relies on molecular genetic testing within the primary lymphatic dysplasia workup

Diagnosis integrates family history, clinical signs (generalized lymphedema, dysmorphism, developmental delay), pathology, and genetic testing:

"Diagnosis of the disease depends on the familial history, clinical signs, pathological findings and genetic tests." — PMID: 25616299

Molecular confirmation is achieved by exome/genome sequencing or a primary-lymphedema gene panel including CCBE1, FAT4, and ADAMTS3, detecting biallelic variants; splice variants can be functionally confirmed by RT-PCR of patient fibroblasts (PMID: 41992670). Gene selection is guided by the standardized Connell/Gordon/Mansour classification and diagnostic algorithm for primary lymphatic dysplasia:

"In 2010, we introduced a new classification and diagnostic pathway as a clinical and research tool. This algorithm has been used to delineate specific primary lymphoedema phenotypes, facilitating the discovery of new causative genes." — PMID: 23621851

Supportive tests include duodenal/intestinal biopsy showing lymphangiectasia, low serum total protein/albumin and low immunoglobulins (PLE), and imaging (Doppler ultrasound, MRI, CT, lymphoscintigraphy/MR lymphangiography) demonstrating lymphatic anomalies and effusions.

Finding 8 — Anatomy, congenital onset, chronic progressive course, and variable prognosis

The primary defect resides in the lymphatic vasculature (UBERON:0001473 lymphatic vessel; lymphatic valve) and affects lymphatic endothelial cells (CL:0002138). Multisystem involvement is documented: limbs (peripheral/generalized lymphedema), intestine/duodenum (intestinal lymphangiectasia, UBERON:0000160), face/craniofacial skeleton (dysmorphism), brain/cerebral cortex (intellectual disability, periventricular heterotopia via FAT4/DCHS1; PMID: 24056717), heart/pericardium (pericardial effusion, cardiac defects; PMID: 38028107), ear (hearing loss), and serous cavities (chylous ascites, pleural/pericardial effusions):

"whose clinical phenotype also includes protein losing enteropathy, painful relapsing chylous ascites, and hypogammaglobulinemia" — PMID: 26686525

Onset is congenital/neonatal, with edema often present at birth or in infancy:

"presented to our center with generalized edema, ascites, and hypoalbuminemia" — PMID: 25925991

The course is chronic and lifelong — generally progressive/fluctuating with episodic effusions and increased infection (cellulitis) risk. Prognosis is variable and is largely determined by the severity of intestinal lymphangiectasia/PLE and of serous effusions (PMID: 38028107, PMID: 29560340).

Section-by-Section Report

1. Disease Information

HKLLS2 is an autosomal recessive generalized lymphatic dysplasia — one of the genetically defined forms of Hennekam syndrome — characterized by congenital lymphedema, intestinal lymphangiectasia, facial dysmorphism, and variable intellectual disability. It is a Mendelian, disease-level (not EHR/individual-patient-derived) entity delineated from aggregated case reports and cohort reviews.

Key identifiers: OMIM #616006; MONDO:0014217; Orphanet ORPHA:2136 (Hennekam syndrome); ICD-10 Q82.0 (hereditary lymphedema); MeSH — "Lymphangiectasis, Intestinal" / "Lymphedema" (no dedicated MeSH term for the FAT4 subtype).

Synonyms / alternative names: Hennekam syndrome type 2; Hennekam lymphangiectasia-lymphedema syndrome 2; lymphedema-lymphangiectasia-mental retardation syndrome (FAT4-related); generalized lymphatic dysplasia, FAT4-type. Allelic disorder: Van Maldergem syndrome 2 (VMS2, FAT4).

2. Etiology

Causal factor: purely genetic — biallelic loss-of-function variants in FAT4 (PMID: 24913602). No environmental or infectious cause.

Genetic risk factors: the disease-defining variants are the causal factor; there are no established susceptibility loci beyond the biallelic FAT4 genotype. Consanguinity is a major contributor because homozygous variants predominate in affected families. A candidate fourth gene, FBXL7, has been proposed on the basis of a homozygous single-exon deletion in a Hennekam-like patient lacking CCBE1/FAT4/ADAMTS3 variants; FBXL7 interacts with Fat in Drosophila, suggesting a shared pathway (PMID: 31633297) — a potential modifier/allelic locus rather than a confirmed HKLLS2 gene.

Environmental / protective factors: none established. No protective alleles or lifestyle factors are known for this monogenic disorder.

Gene–environment interactions: not characterized. Phenotypic variability (expressivity) is likely influenced by modifier genes within the Fat/Dachsous/Hippo network and by the specific residual function of hypomorphic alleles, but this remains inferred rather than demonstrated.

3. Phenotypes

Phenotype Type HPO suggestion Onset Frequency (qualitative)
Generalized/peripheral lymphedema Physical sign HP:0001004 (Lymphedema) Congenital/neonatal Defining feature; distinguishes HS from VMS
Intestinal lymphangiectasia Lab/imaging/pathology HP:0002593 Infancy–childhood Common
Protein-losing enteropathy Lab abnormality HP:0002243 Childhood Common
Facial dysmorphism (flat face, hypertelorism, flat nasal bridge) Physical HP:0001999 / HP:0000316 Congenital Typical facial gestalt
Intellectual disability (mild–moderate) Behavioral/cognitive HP:0001256 Childhood Frequent, variable
Hypoalbuminemia Lab abnormality HP:0003073 Infancy Common (secondary to PLE)
Hypogammaglobulinemia Lab abnormality HP:0004313 Infancy Reported
Chylous ascites / pleural / pericardial effusion Sign/imaging HP:0012019 / HP:0001541 Variable Reported
Hearing loss Sensory HP:0000365 Variable Reported (more typical of VMS)
Camptodactyly Physical HP:0012385 Congenital Reported
Hypotonia Neurological HP:0001252 Neonatal Reported

Severity is variable and the course is chronic-progressive/fluctuating. Quality-of-life impact is substantial: chronic lymphedema limits mobility and predisposes to recurrent cellulitis; PLE causes failure to thrive, immunodeficiency, and effusions; intellectual disability affects independent functioning. No disease-specific QoL instrument (EQ-5D/SF-36/PROMIS) data exist for this ultra-rare condition.

4. Genetic / Molecular Information

Causal gene: FAT4 (HGNC:23109; NCBI Gene 79633; Ensembl ENSG00000196159; UniProt Q6V0I7; 4q28.1). Protein: ~4,981-aa single-pass atypical cadherin with 34 extracellular cadherin repeats, EGF-like domains, and laminin-G domains — vertebrate ortholog of Drosophila Fat (PMID: 28488382).

Pathogenic variants: biallelic (homozygous in consanguineous families or compound heterozygous), predominantly loss-of-function — missense, nonsense, frameshift, and splice-site. Example: novel intron-14 biallelic splice variant c.12479+3A>G with RT-PCR-confirmed aberrant splicing (PMID: 41992670). Classification per ACMG/AMP: reported variants range from pathogenic to likely pathogenic; loss-of-function is the consistent functional consequence. These variants are absent or ultra-rare in population databases (gnomAD) in the homozygous state.

Functional consequence: loss of function / reduced FAT4 signaling.

Modifier genes: DCHS1 (FAT4's cognate ligand) and downstream Hippo/YAP effectors; FBXL7 proposed as a pathway member/candidate gene (PMID: 31633297). Epigenetic/chromosomal abnormalities: none specific to HKLLS2; single-exon deletions (e.g., in FBXL7) illustrate that copy-number changes in pathway genes can produce a Hennekam-like phenotype.

5. Environmental Information

Not applicable — HKLLS2 is a monogenic disorder with no established environmental, lifestyle, or infectious contributors. Environmental factors may modulate secondary complications (e.g., skin trauma precipitating cellulitis, dietary fat load exacerbating lymphangiectasia) but are not causal.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

  1. Biallelic loss-of-function FAT4 variants → loss/reduction of functional FAT4 atypical cadherin protein. (Demonstrated — PMID: 24913602)
  2. Loss of FAT4 → disrupted Fat4–Dachsous1 (DCHS1) planar cell polarity signaling at the cell surface. (Demonstrated in mouse/fly — PMID: 28705793, PMID: 18604206)
  3. In lymphatic endothelial cells, disrupted PCP → failure of flow-responsive LEC polarization (FAT4 is a GATA2 transcriptional target). (Demonstrated — PMID: 32182215)
  4. Failed LEC polarization → defective lymphatic valve and vessel morphogenesis, converging on the VEGF-C/VEGFR3 axis that CCBE1/ADAMTS3 also feed. (Demonstrated — PMID: 28705793, PMID: 32182215)
  5. Defective valves/vessels → impaired lymphatic drainage and lymph stasis → congenital generalized lymphedema. (Inferred from valve defects → clinical lymphedema)
  6. Branch — intestine: dysfunctional intestinal lymphatics → intestinal lymphangiectasia → leakage of lymph/protein into gut lumen → protein-losing enteropathy → hypoalbuminemia + hypogammaglobulinemia → worsening interstitial edema, effusions, immunodeficiency. (Demonstrated as downstream consequence — PMID: 38028107)
  7. Branch — brain: loss of FAT4/DCHS1 → increased neural progenitor proliferation, reduced neuronal differentiation via Hippo/YAP → cortical malformation/periventricular heterotopia → intellectual disability. (Demonstrated in mouse — PMID: 24056717)
  8. Branch — craniofacial/other: disrupted PCP-dependent tissue morphogenesis → facial dysmorphism, skeletal and sensory (hearing) anomalies. (Inferred)
   FAT4 biallelic LOF variants
     │
   ↓ loss of FAT4 atypical cadherin
     │
   ↓ disrupted FAT4–DCHS1 PCP + Hippo/YAP signaling
┌────────────┬───────────────┬─────────────┐
↓            ↓               ↓             ↓
   LEC polarity   neural progenitor  craniofacial   (kidney/PCP
   failure        overproliferation  morphogenesis   in models)
↓            ↓               ↓
   valve/vessel   ↓ neuronal diff.   facial
   defect         (YAP-dependent)    dysmorphism
↓            ↓
   lymph stasis   cortical heterotopia
   ┌──────┴──────┐   ↓
   ↓             ↓  intellectual disability
generalized   intestinal
lymphedema    lymphangiectasia
          ↓
      protein-losing enteropathy
          ↓
  hypoalbuminemia, hypogammaglobulinemia,
  chylous effusions, immunodeficiency

Molecular pathways: Fat/Dachsous planar cell polarity; Hippo/YAP; VEGF-C/VEGFR3 (FLT4) prolymphangiogenic signaling. Cellular processes: endothelial cell polarization, oriented cell division, valve morphogenesis, neural progenitor differentiation. Protein dysfunction: loss of function of a giant atypical cadherin (impaired cell–cell adhesion/signaling). Immune involvement: secondary hypogammaglobulinemia from PLE (loss of immunoglobulins), not primary autoimmunity. GO term suggestions: GO:0001945 (lymph vessel development), GO:0001938 (positive regulation of endothelial cell proliferation), GO:0001736 (establishment of planar polarity), GO:0035329 (Hippo signaling). Cell types (CL): CL:0002138 (endothelial cell of lymphatic vessel); neural progenitor cells. CHEBI: medium-chain triglycerides (therapeutic entity class).

7. Anatomical Structures Affected

  • Primary organ/system: lymphatic vasculature (UBERON:0001473 lymphatic vessel; lymphatic valve) — cardiovascular/lymphatic system.
  • Secondary organs: intestine/duodenum (UBERON:0000160; intestinal lymphangiectasia, PLE); brain/cerebral cortex (UBERON:0000956; intellectual disability, heterotopia); face/craniofacial skeleton (dysmorphism); heart/pericardium (effusions, cardiac defects); ear (hearing loss); serous cavities (peritoneal, pleural, pericardial — chylous effusions).
  • Tissue/cell level: lymphatic endothelium (CL:0002138); neuroepithelial progenitors; connective/soft tissue (edema).
  • Subcellular: plasma membrane cadherin signaling complex (GO:0005886 plasma membrane); cell junctions.
  • Lateralization: lymphedema is typically generalized/bilateral rather than unilateral.

8. Temporal Development

  • Onset: congenital/neonatal; edema frequently present at birth or in early infancy (PMID: 25925991, PMID: 41992670).
  • Progression: chronic, lifelong; generally progressive with fluctuating/episodic exacerbations (effusions, cellulitis). Intestinal lymphangiectasia/PLE may worsen over time.
  • Course pattern: chronic progressive with episodic complications; no spontaneous remission of the underlying lymphatic defect (symptomatic control possible with therapy).
  • Critical periods: perinatal/early infancy for edema and PLE onset; early childhood for developmental/cognitive support.

9. Inheritance and Population

  • Epidemiology: ultra-rare. Hennekam syndrome overall has ~50 reported cases worldwide (as of 2023; PMID: 38028107); Orphanet prevalence <1/1,000,000. CCBE1 accounts for ~25% of Hennekam cases; FAT4 explains a further genetically heterogeneous subset (PMID: 24913602).
  • Inheritance: autosomal recessive; biallelic (homozygous or compound heterozygous) FAT4 variants.
  • Penetrance/expressivity: presumed high penetrance for biallelic LOF; expressivity is variable (severity of lymphedema, PLE, and cognitive impairment differ between families). Van Maldergem vs Hennekam presentations from the same gene illustrate marked phenotypic variability.
  • Consanguinity: important — homozygous variants are frequently found in consanguineous families.
  • Founder effects / carrier frequency: none established; carrier frequency is not quantified given rarity.
  • Sex ratio: no sex predilection (autosomal recessive; M≈F).

10. Diagnostics

  • Clinical/laboratory: low serum total protein and albumin (hypoalbuminemia), low immunoglobulins (hypogammaglobulinemia) from PLE; fecal alpha-1-antitrypsin (PLE marker, inferred).
  • Imaging: Doppler ultrasound, MRI, CT; lymphoscintigraphy and MR lymphangiography demonstrating lymphatic anomalies, lymphangiomas, and effusions.
  • Pathology/biopsy: duodenal/intestinal biopsy showing dilated lacteals/lymphangiectasia (PMID: 25616299).
  • Genetic testing (confirmatory): whole-exome or whole-genome sequencing, or a primary-lymphedema/lymphatic-dysplasia gene panel including CCBE1, FAT4, ADAMTS3; detection of biallelic variants. Splice variants confirmed functionally by RT-PCR of patient fibroblasts (PMID: 41992670). Chromosomal microarray can detect exon/CNV deletions in pathway genes (PMID: 31633297).
  • Diagnostic framework: the Connell/Gordon/Mansour classification and diagnostic algorithm for primary lymphatic dysplasia guides workup and gene selection (PMID: 23621851).
  • Differential diagnosis: Hennekam syndrome types 1 (CCBE1) and 3 (ADAMTS3); Van Maldergem syndrome (allelic FAT4/DCHS1); other primary lymphedemas (Milroy disease/FLT4, lymphedema-distichiasis/FOXC2); Noonan syndrome with lymphatic involvement; primary intestinal lymphangiectasia (Waldmann disease) without syndromic features.

11. Outcome / Prognosis

Prognosis is variable and depends chiefly on the severity of intestinal lymphangiectasia/PLE and of serous effusions. Chronic PLE causes failure to thrive, immunodeficiency (recurrent infections), and refractory effusions; severe lymphedema predisposes to recurrent cellulitis. No formal survival statistics exist given rarity; life expectancy can be reduced in severe cases but many patients survive into adulthood with supportive care. Morbidity is dominated by chronic lymphedema, PLE-related nutritional/immunologic compromise, and intellectual disability. Prognostic factors: severity/extent of lymphatic dysplasia, degree of hypoalbuminemia/hypogammaglobulinemia, and presence of cardiac/pericardial involvement (PMID: 38028107, PMID: 29560340).

12. Treatment

No curative therapy exists (PMID: 29560340). Management is supportive:

  • Lymphedema: complete decongestive therapy — manual lymphatic drainage, multilayer compression, exercise, meticulous skin care (NCIT: Complete Decongestive Therapy / Physical Therapy).
  • Intestinal lymphangiectasia / PLE: high-protein, low-fat, medium-chain-triglyceride (MCT) diet (NCIT: Dietary Intervention); parenteral albumin and immunoglobulin replacement as needed; consideration of octreotide in refractory PLE (inferred from general lymphangiectasia management).
  • Effusions: drainage of chylous ascites/pleural/pericardial effusions; dietary fat restriction (PMID: 26686525).
  • Surgical/interventional: treatment of localized lymphatic malformations; symptomatic surgery for effusions.
  • Multidisciplinary symptomatic care: developmental/educational support for intellectual disability, audiology for hearing loss, cardiology for cardiac anomalies, genetics/genetic counseling.
  • Experimental/targeted: no approved targeted therapy; the shared VEGF-C/VEGFR3 axis is a plausible future therapeutic node but is unproven in HKLLS2. No pharmacogenomic considerations established.

13. Prevention

  • Primary prevention: not possible (genetic); genetic counseling of at-risk (especially consanguineous) families.
  • Secondary/tertiary prevention: early detection and management of PLE, effusions, and cellulitis to prevent complications; compression therapy to slow lymphedema progression.
  • Genetic screening: carrier testing of relatives once the familial FAT4 variants are known; prenatal diagnosis and preimplantation genetic testing available for known biallelic variants.
  • Counseling: recurrence risk 25% for offspring of two carriers; cascade testing recommended.

14. Other Species / Natural Disease

  • Taxonomy/orthologs: mouse Fat4 (NCBI Taxon 10090), Drosophila fat (Taxon 7227). FAT4 is the vertebrate ortholog of Drosophila Fat.
  • Natural disease: no well-characterized naturally occurring FAT4-lymphedema disorder in companion animals or wildlife is documented (OMIA — no established entry for a FAT4-Hennekam animal disease).
  • Comparative biology: the Fat/Dachsous/Hippo PCP module is deeply evolutionarily conserved from Drosophila to mammals, and loss-of-function reproduces morphogenetic defects (kidney cysts, neural over-proliferation, lymphatic valve defects) across species.

15. Model Organisms

Model Type Genetic manipulation Phenotype recapitulated Reference
Mouse (Mus musculus) Mammalian Fat4 knockout / knockdown Cystic kidney (PCP/oriented division defect); interacts with Vangl2, Fjx1 PMID: 18604206
Mouse Mammalian Dchs1/Fat4 neuroepithelial knockdown Increased progenitors, reduced neuronal differentiation, periventricular heterotopia; rescued by Yap knockdown PMID: 24056717
Mouse Mammalian Fat4-deficient Defective lymphatic valve morphogenesis and LEC polarity PMID: 28705793, PMID: 32182215
Drosophila melanogaster Invertebrate Neuron-specific fat knockdown Shortened lifespan, impaired locomotion, motoneuron/axon-targeting defects (relevant to intellectual disability) PMID: 28488382

Model applications: dissecting PCP/Hippo signaling, lymphatic valve development, cortical neurogenesis, and organ morphogenesis. Limitations: no single model fully reproduces the complete human multisystem phenotype (lymphedema + PLE + dysmorphism + cognitive impairment simultaneously); embryonic lethality of full knockouts necessitates conditional/tissue-specific approaches. Resources: MGI (mouse), FlyBase (Drosophila), IMPC/IMSR for allele repositories.

Mechanistic Model / Interpretation

HKLLS2 is best understood as a planar-cell-polarity/Hippo signaling disorder with a dominant lymphatic phenotype. The unifying lesion is loss of the giant atypical cadherin FAT4, which normally partners with Dachsous1 to transmit tissue-level polarity information and to restrain YAP-driven proliferation. In the lymphatic endothelium this polarity signal is required for cells to align to flow and construct competent valves and vessels — so its loss produces lymph stasis and the congenital lymphedema, intestinal lymphangiectasia, and chylous effusions that dominate the clinical picture. In the developing cortex the same signal restrains progenitor proliferation and promotes neuronal differentiation, so its loss yields heterotopia and intellectual disability. Because CCBE1 and ADAMTS3 (the other Hennekam genes) act on the parallel VEGF-C/VEGFR3 activation step required to build lymphatics, mutations in any of the three genes converge on failure of functional lymphatic development, explaining the shared Hennekam phenotype despite distinct molecular entry points. This convergence is the central mechanistic insight of the report and is supported by both human genetics and mouse/fly models.

Evidence Base

PMID Title (abbrev.) Contribution
24913602 FAT4 mutations cause Hennekam syndrome, allelic to VMS Establishes FAT4 as causal gene; AR inheritance; CCBE1 ~25%
30450763 ADAMTS3 loss-of-function in Hennekam Confirms OMIM #616006 and AR; third gene
32182215 FAT4 orchestrates LEC polarity in response to flow Cell-autonomous LEC mechanism; VEGF-C/VEGFR3 convergence
28705793 Dachsous1-Fat4 signaling in lymphatic valve morphogenesis Links valve defects to lymphedema
29681106 VMS and HS allelic phenotypes Clinical spectrum; HS vs VMS distinctions
38028107 Newfound features of Hennekam Syndrome PLE consequence; ~50 cases worldwide
24056717 DCHS1/FAT4 disrupt cortical development Neurodevelopmental mechanism; Hippo/YAP
18604206 Loss of Fat4 disrupts PCP → cystic kidney Mouse PCP mechanism
28488382 Drosophila fat neuronal knockdown Protein domains; neuronal model
29560340 Hennekam Syndrome case report No curative therapy; CDT beneficial
23621851 Primary lymphatic dysplasia classification Diagnostic algorithm
41992670 FAT4 c.12479+3A>G splice variant Variant spectrum; RT-PCR confirmation
25616299 Complicated Hennekam case Multimodal diagnosis; biopsy
26686525 CCBE1 multiplex kindred Chylous ascites, hypogammaglobulinemia
25925991 Novel CCBE1 mutation, mild HS Neonatal onset with generalized edema
27159393 Proteolytic activation of VEGFC/VEGFD ADAMTS3-CCBE1 activates VEGF-C
28687807 VEGF-C activation requires CCBE1 domains Molecular detail of pathway
29842991 Key molecules in lymphatic development PROX1/VEGFR3/CCBE1/ADAMTS3 backbone
31633297 FBXL7 biallelic mutation, novel HS form Candidate 4th gene in FAT4 pathway

Limitations and Knowledge Gaps

  1. Small evidence base: ~50 Hennekam cases total worldwide and only a subset are FAT4-positive, so all frequencies are qualitative; no formal penetrance, expressivity, survival, or QoL statistics exist.
  2. Genotype–phenotype correlation between HKLLS2 and allelic Van Maldergem syndrome is incompletely understood — why the same gene produces lymphedema in some patients and not others is unresolved.
  3. No natural-history or registry data to quantify progression rate or complication incidence.
  4. No dedicated animal model reproduces the full multisystem human phenotype simultaneously.
  5. Therapeutics: no targeted therapy has been tested; the VEGF-C/VEGFR3 node is a theoretical target only.
  6. Modifier genes (DCHS1, FBXL7, Hippo effectors) are hypothesized but not validated as clinical modifiers.
  7. Several ontology mappings (specific UBERON/CL/GO terms) are suggested rather than curated for this specific disease.

Proposed Follow-up Experiments / Actions

  1. Assemble an international FAT4-HKLLS2 patient registry to quantify phenotype frequencies, penetrance, expressivity, and natural history.
  2. Genotype–phenotype study correlating specific FAT4 variant type/location with lymphatic vs neurodevelopmental vs VMS-like presentations.
  3. LEC-specific conditional Fat4 mouse with lymphatic-valve and intestinal-lymphatic readouts to model the full HKLLS2 lymphatic phenotype and test VEGF-C/VEGFR3 pathway modulation.
  4. Functional validation of candidate genes/modifiers (FBXL7, DCHS1) in the Fat4 pathway using patient fibroblasts/organoids.
  5. Evaluate MCT-diet, octreotide, and albumin/Ig-replacement protocols prospectively for PLE control in this population.
  6. Curate definitive ontology annotations (HPO frequencies, UBERON, CL, GO, NCIT) for knowledge-base ingestion.

Report compiled from 8 confirmed findings and 23 reviewed papers across 5 investigation iterations. Evidence types: human clinical (case reports, cohort reviews, molecular genetics), model organism (mouse, Drosophila), and in vitro/biochemical (VEGF-C activation studies).

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 19
Resolved 19
Unresolved (possible confabulation) 0
Unverifiable 0
Quoted claims checked 18
Quoted claims found in source 18
Quoted claims not found in source 0
References weighed for topical relevance 19
On topic 13
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 25
Resolved 23
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 2
Terms whose name was checked 14
Terms named correctly 5
Terms named as a different term 8
Terms whose name is worth a second look 1

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • HP:0002593 (1 mention) - the report calls it "Lab/imaging/pathology"; HP calls it Intestinal lymphangiectasia
  • HP:0002243 (1 mention) - the report calls it "Lab abnormality"; HP calls it Protein-losing enteropathy
  • HP:0001256 (1 mention) - the report calls it "Behavioral/cognitive"; HP calls it Mild intellectual disability
  • HP:0003073 (1 mention) - the report calls it "Lab abnormality"; HP calls it Hypoalbuminemia
  • HP:0004313 (1 mention) - the report calls it "Lab abnormality"; HP calls it Decreased circulating immunoglobulin concentration
  • HP:0000365 (1 mention) - the report calls it "Sensory"; HP calls it Hearing impairment
  • HP:0012385 (1 mention) - the report calls it "Physical"; HP calls it Camptodactyly
  • HP:0001252 (1 mention) - the report calls it "Neurological"; HP calls it Hypotonia

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • CL:0002138 (3 mentions) - the report calls it "lymphatic endothelial cells", "endothelial cell of lymphatic vessel", "Tissue/cell level: lymphatic endothelium"; CL calls it endothelial cell of lymphatic vessel**

Terms named inconsistently

The report gives these identifiers more than one name of its own:

  • CL:0002138 - called "lymphatic endothelial cells", "endothelial cell of lymphatic vessel", "Tissue/cell level:** lymphatic endothelium"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.